pyrroles has been researched along with Rheumatoid Arthritis in 428 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 60 (14.02) | 18.7374 |
| 1990's | 1 (0.23) | 18.2507 |
| 2000's | 25 (5.84) | 29.6817 |
| 2010's | 270 (63.08) | 24.3611 |
| 2020's | 72 (16.82) | 2.80 |
| Authors | Studies |
|---|---|
| Iwasawa, M; Juji, T; Maenohara, Y; Matsumoto, T; Nakamura, I; Omata, Y; Takahashi, H; Tanaka, S; Uchio, A | 1 |
| Feng, Y; Shi, Y; Xie, Y; Zhang, G | 1 |
| Bensimon, A; Bergman, M; Clewell, J; Orvis, E; Tundia, N; Yang, M | 1 |
| Bode-Böger, SM; Feist, E; Martens-Lobenhoffer, J; Tomaras, S | 1 |
| Choy, EH; Dews, SA; Galloway, J; Raine, T; Rivett, L; Roberts, J | 1 |
| Desai, RJ; Khosrow-Khavar, F; Kim, SC; Lee, H; Lee, SB | 1 |
| Askling, J; Barbulescu, A; Chatzidionysiou, K; Forsblad-d'Elia, H; Frisell, T; Kastbom, A; Lindström, U; Turesson, C | 1 |
| Bessette, L; Kinch, CD; Kwok, K; Lukic, T; Mysler, E; On, PV; van Vollenhoven, RF | 1 |
| Abello, M; Amador, L; Castillo, D; Gutierrez-Ardila, MV; Guzman, R; Izquierdo, J; Lukic, T; Madariaga, H; Otero, W; Ponce de Leon, D; Reyes, J; Velez, P | 1 |
| Cohen, SB; Winthrop, KL | 1 |
| Bartlett, SJ; Bingham, CO; Cella, D; Gold, DA; Gruben, D; Murray, C; van Vollenhoven, R | 1 |
| Llevat, N; Montoro, M; Román Ivorra, JA | 1 |
| Arbrile, M; Baldovino, S; Barinotti, A; Buccarano, N; Cecchi, I; Crosasso, P; Di Gregorio, F; Di Nunzio, P; Favuzzi, MD; Menegatti, E; Milone, V; Osella, S; Radin, M; Roccatello, D; Rossi, D; Sciascia, S | 1 |
| Álvaro-Gracia, JM; Curtis, JR; Dikranian, AH; Gonzalez-Gay, MA; Paulissen, J; Shi, H; Stockert, L; Takiya, L; Tatulych, S; Wellborne, F | 1 |
| Amin, S; Khenat, A; Malandkar, M; Phatak, S | 1 |
| Choquette, D; Galos, C; Gruben, D; Haraoui, B; Keystone, EC; Khraishi, M; Kinch, C; Lisnevskaia, L; Roy, P; Sampalis, JS; Teo, M; Vaillancourt, J; Woolcott, JC | 1 |
| Landewé, R; Ramiro, S; van der Heijde, D | 1 |
| Leng, X; Sun, B; Yang, H; Zeng, X; Zhang, W; Zhou, J; Zhou, S | 1 |
| Balanescu, AR; Bhatt, DL; Chen, AS; Citera, G; Connell, CA; Gold, D; Pascual-Ramos, V; Pope, JE; Sawyerr, G; Schulze-Koops, H; Shapiro, AB | 1 |
| Jung, JY; Kim, HA; Kim, JW; Lee, E; Suh, CH | 1 |
| Isomäki, P; Kuuliala, A; Kuuliala, K; Leirisalo-Repo, M; Palmroth, M; Peltomaa, R; Silvennoinen, O; Valli, A; Vidqvist, KL; Virtanen, A | 1 |
| Cañada Martínez, AJ; Fragío Gil, JJ; González Mazarío, R; González Puig, L; Grau García, E; Ivorra Cortés, J; Negueroles Albuixech, RM; Román Ivorra, JA | 1 |
| Charles-Schoeman, C; Hyde, C; Martin, DA; Paciga, SA; Sahin, B; Szekanecz, Z; Vranic, I; Wang, Z; Weitz, JI | 1 |
| Jeon, JY; Jo, JY; Ju, JH; Lee, EB; Sung, YK; Yoo, HJ | 1 |
| Bertolini, N; Caso, F; Costa, L; Del Puente, A; Luppino, JME; Mostacciuolo, E; Passavanti, S; Peluso, R; Santelli, F; Scarpa, R; Tasso, M | 1 |
| Bhatt, DL; Chen, YH; Connell, CA; Curtis, JR; Gómez-Reino, JJ; Gunay, LM; Menon, S; Sugiyama, N; Vranic, I; Wang, C; Wu, J; Yamaoka, K | 1 |
| Bhatt, DL; Buch, MH; Charles-Schoeman, C; Connell, CA; Dougados, M; Giles, JT; Koch, GG; Kwok, K; Menon, S; Rivas, JL; Szekanecz, Z; Vranic, I; Wang, C; Wu, J; Yndestad, A; Ytterberg, SR | 1 |
| Bingham, CO; Brault, Y; Dougados, M; Fallon, L; Kessouri, M; Roychoudhury, S; Taylor, PC; Wang, L | 1 |
| Ding, NS; Gilmore, R; Tassone, D | 1 |
| Cheng, X; Dai, SM; Du, F; Hu, Q; Jiang, L; Liu, H; Lu, LJ; Ma, L; Shi, H; Su, Y; Tao, YL; Teng, J; Wang, M; Xue, Y; Yang, C; Ye, J; Zhao, D | 1 |
| Keystone, EC; Mokbel, A; Movahedi, M; Ojani, P; Philippopoulos, E | 1 |
| Barton, A; Bluett, J; Church, S; Hyrich, KL; Ogungbenro, K; Unwin, RD | 1 |
| Danese, S; Lasa, JS; Olivera, PA; Peretto, G; Peyrin-Biroulet, L; Zuily, S | 1 |
| Choe, JY; Jeon, JY; Kim, SK; Lee, SH; Sun, J; Yoo, HJ | 1 |
| Atsumi, T; Bracher, M; Brooks, D; Davies, J; Fleischmann, RM; Goode, C; Gupta, A; McInnes, IB; Mukherjee, S; O'Shea, C; Saurigny, D; Schifano, LA; Shelton, C; Smith, JE; Strand, V; Takeuchi, T; Taylor, PC; van der Heijde, D; Wang, M; Wang, R; Watts, S; Weinblatt, ME | 1 |
| Ciurea, A; Distler, O; Frank Bertoncelj, M; Jo, H; Killeen, T; Kwok, K; Ospelt, C; Wang, L | 1 |
| Mori, S; Ueki, Y | 1 |
| Bessette, L; Crooks, M; Fallon, L; Gold, D; Gruben, D; Haraoui, B; Jones, N; Pope, J; Woolcott, J | 1 |
| Krüger, K | 1 |
| Andrews, J; Bowes, MA; Chapman, D; Conaghan, PG; Guillard, G; Koenig, A; Stein, A; Troum, O; Wilkinson, B; Xie, Z; Østergaard, M | 1 |
| Abria, C; Chaudhari, AJ; Harmany, ZT; Kundu-Raychaudhuri, S; Raychaudhuri, S; Raychaudhuri, SP; Smith, CM | 1 |
| DeMasi, R; Fleischmann, R; Gruben, D; Iikuni, N; Moots, RJ; Mysler, E; Smolen, JS; Soma, K; Strand, V; Wallenstein, GV | 1 |
| Choy, EH | 2 |
| Lei, Y; Li, Y; Lu, J; Shen, H; Xia, L; Yang, J; Yuan, L; Zhang, H | 1 |
| Lee, YH; Song, GG | 3 |
| Hayashi, S; Itoh, I; Iwano, M; Kasuno, K; Kimura, H; Ojima, T; Shimizu, H; Takahashi, N; Yamamoto, C | 1 |
| Kato, F; Kurosaka, D; Oto, Y; Takahashi, Y | 1 |
| Dowty, ME; Hegen, M; Jesson, MI; Katkade, V; Lin, TH; Martin, DA; Menon, S; Telliez, JB | 1 |
| Chandran, U; Reps, J; Ryan, PB; Stang, PE | 1 |
| Bonovas, S; Danese, S; Lasa, JS; Olivera, PA; Peyrin-Biroulet, L | 1 |
| Bertoldi, I; Orsolini, G; Rossini, M | 1 |
| Estevez, AJ; Papagno, MJ; Vinicki, JP | 1 |
| Biswas, P; Chen, C; Choy, EH; Needle, E; Rigby, WF; Soma, K; Valdez, H; Wang, L; Winthrop, KL; Wouters, A | 1 |
| Damsky, W; King, B; Peterson, D | 1 |
| Betts, KA; Du, EX; Pope, J; Qi, CZ; Sawant, R; Song, Y; Tang, P; Tundia, N | 1 |
| Balsa, A; Casado, MA; de Andrés-Nogales, F; Gómez, S; Martinez-Sesmero, JM; Montoro, M; Navarro, F; Oyagüez, I; Peral, C; Valderrama, M | 1 |
| Banfield, C; Beebe, JS; Chandra, D; Cox, L; Damjanov, N; Kivitz, A; Mancuso, J; Manukyan, Z; Peeva, E; Radunovic, G; Robinson, MF; Saunders, M; Stamenkovic, B; Vincent, MS | 1 |
| Baldovino, S; Buccarano, N; Cecchi, I; Crosasso, P; Di Gregorio, F; Di Nunzio, P; Favuzzi, MD; Foddai, SG; Osella, S; Radin, M; Roccatello, D; Rossi, D; Rubini, E; Sciascia, S; Valeria, M | 1 |
| Morinobu, A | 1 |
| Alikhan, M; Jogi, R; Nguyen, JK; Patel, AB; Schlichte, MJ | 1 |
| Kobak, S | 1 |
| Cardiel, MH; Castañeda, O; Chartrand, S; Citera, G; Fischer, A; Girard, T; Kwok, K; Madariaga, H; Mysler, E; Park, JK; Ponce de Leon, D; Richette, P; Rivas, JL; Strengholt, S; Thorat, AV; Wang, L | 1 |
| Armuzzi, A; Colombel, JF; Farnier, M; Friedman, GS; Ha, C; Kwok, K; Quirk, D; Salese, L; Sands, BE; Su, C; Taub, PR | 1 |
| Chen, Y; Dong, P; Guo, Q; Ma, A; Tian, L; Wang, L; Xiong, X | 1 |
| Dörner, T | 1 |
| Chen, DY; Chen, HH; Chen, JP; Chen, YH; Chen, YJ; Chen, YM; Hsieh, TY; Huang, WN; Liao, TL | 1 |
| Blachley, T; Chen, C; Cohen, SB; Dandreo, KJ; Dougados, M; Greenberg, JD; Gruben, D; Harnett, J; Lenihan, A; Litman, HJ; Lukic, T; Madsen, A; Rivas, JL; Smith, TW; Woolcott, J; Zhang, R | 1 |
| Alten, R; Diehl, A; Germino, R; Kaine, J; Murray, CW; Shi, H; Strand, V; Wallenstein, G | 1 |
| Kadoba, K; Mukoyama, H; Murabe, H; Nishimura, K; Saito, R; Waki, D; Yokota, T | 1 |
| Biswas, P; Charles-Schoeman, C; Chen, C; Cohen, SB; Curtis, JR; Kwok, K; Lee, EB; Madsen, A; Mariette, X; Nash, P; Shapiro, A; Tanaka, Y; Wang, L; Winthrop, KL; Wollenhaupt, J | 1 |
| Amuro, H; Ebina, K; Hara, R; Hashimoto, M; Hirano, T; Hirao, M; Jinno, S; Katayama, M; Kumanogoh, A; Maeda, Y; Murata, K; Nakata, K; Okita, Y; Onishi, A; Son, Y; Takeuchi, T; Yamamoto, K; Yamamoto, W; Yoshikawa, A | 1 |
| Bhattoa, HP; Bodnár, N; Bodoki, L; Czókolyová, M; Domján, A; Gulyás, K; Hamar, A; Hodosi, K; Horváth, Á; Nagy, G; Panyi, G; Pethő, Z; Pusztai, A; Soós, B; Szamosi, S; Szántó, S; Szekanecz, É; Szekanecz, Z; Szűcs, G; Tajti, G; Végh, E | 1 |
| Lee, YH; Sung, YK | 1 |
| Li, Y; Sun, Y; Wei, S; Zhang, L; Zong, S | 1 |
| Avci, AB; Burmester, GR; Feist, E | 1 |
| Aramaki, T; Eguchi, K; Endo, Y; Fujikawa, K; Ichinose, K; Igawa, T; Iwamoto, N; Kawakami, A; Kawashiri, SY; Koga, T; Kurushima, S; Michitsuji, T; Mizokami, A; Nakamura, H; Nishihata, S; Okada, A; Okamoto, M; Origuchi, T; Sato, S; Shimizu, T; Sumiyoshi, R; Suzuki, T; Tamai, M; Tsuji, Y; Ueki, Y | 1 |
| Barbich, T; Cerda, OL; Citera, G; Schneeberger, EE | 1 |
| Cernea, M; Gupta, AK; Lynde, CW | 1 |
| Bijlsma, J; Burmester, G; Chatzidionysiou, K; Dougados, M; Emamikia, S; Landewé, R; Nam, J; Ramiro, S; Scholte, M; Smolen, J; van der Heijde, D; van Vollenhoven, R | 1 |
| Mitchell, TS; Moots, RJ; Wright, HL | 1 |
| Handa, H; Hosogai, M; Kishi, S; Mitsui, T; Ogawa, Y; Todokoro, D; Yanagisawa, K; Yokohama, A | 1 |
| Amano, K; Iwata, K; Kubo, S; Nagano, S; Nagasawa, H; Suematsu, E; Tanaka, Y; Tohma, S; Yamaoka, K | 1 |
| Kosinski, M; Mebus, CA; Rendas-Baum, R; Singh, A; Wallenstein, GV; Wilkinson, BE | 1 |
| Amital, H; Gertel, S; Karmon, G; Mahagna, H; Watad, A | 1 |
| Aramaki, T; Eguchi, K; Fukui, S; Hirai, Y; Horai, Y; Ichinose, K; Iwamoto, N; Kawakami, A; Kawashiri, SY; Koga, T; Nakamura, H; Nishino, A; Origuchi, T; Shimizu, T; Takatani, A; Tamai, M; Terada, K; Tsuji, S; Ueki, Y; Umeda, M | 1 |
| Buchbinder, R; Hossain, A; Maxwell, LJ; Mudano, AS; Singh, JA; Suarez-Almazor, ME; Tanjong Ghogomu, E; Tugwell, P; Wells, GA | 1 |
| Barrow, AD; Capuder, K; Cella, M; Colonna, M; Gilfillan, S; Lin, LL; Notarangelo, LD; Robinette, ML; Telliez, JB; Ulland, TK | 1 |
| Haeffner, F; Hoveyda, AH; Mikus, MS; Mszar, NW; Torker, S | 1 |
| Abdel, MP; Brause, B; Chen, AF; Dasa, V; George, M; Gewurz-Singer, O; Giles, JT; Gililland, J; Goodman, M; Goodman, SM; Guyatt, G; Hurley-Rosenblatt, A; Johnson, B; Kirou, K; Lee, S; Losina, E; MacKenzie, R; Mandl, LA; Michaud, K; Mikuls, T; Miller, AS; Mont, MA; Russell, L; Sah, A; Sculco, P; Singh, JA; Sporer, S; Springer, B; Stryker, L; Turgunbaev, M; Yates, A | 2 |
| Scott, DL; Stevenson, MD | 1 |
| DeMasi, R; Fleischmann, R; Hall, S; Kivitz, AJ; Krishnaswami, S; Luo, Z; Menon, S; Mojcik, C; Moots, RJ; Mysler, E; Smolen, JS; Soma, K; Takiya, L; Tatulych, S; Zhang, R | 1 |
| Barrasa, JI; Gratal, P; Herrero-Beaumont, G; Largo, R; Larrañaga-Vera, A; Pérez-Baos, S; Prieto-Potin, I | 1 |
| Chen, DY; Chen, YH; Chen, YM; Hsieh, TY; Huang, WN; Lin, CT; Wu, YD | 1 |
| Onuora, S | 2 |
| Fujishiro, M; Hayakawa, K; Hirai, T; Ikeda, K; Miyashita, T; Morimoto, S; Sekigawa, I; Takamori, K; Takasaki, Y; Tamura, N; Tsushima, H; Yamaji, K; Yoshida, Y | 1 |
| Betts, KA; Curtis, JR; Douglas, K; Du, EX; Ganguli, A; Wells, AF | 1 |
| Chen, Y; Gao, XM; Gong, FY; Gong, Z; Li, ZJ; Ma, SY; Zhou, Z | 1 |
| Poorvashree, J; Suneela, D | 1 |
| Fleischmann, R | 3 |
| Cush, JJ | 1 |
| Biswas, P; Choy, EH; Hodge, JA; Mojcik, CF; Nduaka, CI; Needle, E; Passador, S; Rigby, WF; Soma, K; Winthrop, KL; Wouters, AG | 1 |
| Bananis, E; Chen, C; Curtis, JR; Fan, H; Hirose, T; Lindsey, S; Mendelsohn, AM; Nduaka, CI; Tanaka, Y; Valdez, H; Wang, L; Winthrop, KL; Yamaoka, K | 1 |
| McHugh, J | 1 |
| Biswas, P; Boy, MG; Chen, C; Kwok, K; Mariette, X | 1 |
| Chen, L; He, L; Lan, T; Pei, H; Tang, M; Zhang, C | 1 |
| Amano, K; Hatta, K; Kanazawa, T; Kume, K; Kuwaba, N; Ohta, H; Yamada, S | 1 |
| Chastek, B; Chen, CI; Kuznik, A; Proudfoot, C; Shinde, S; Wei, W | 1 |
| Deleuran, B; Eggertsen, PP; Frøling, M; Mikkelsen, C; Stern, M; van de Looij, A | 1 |
| Dhillon, S | 1 |
| Bananis, E; Burmester, GR; Charles-Schoeman, C; Connell, CA; Fan, H; Fleischmann, R; Kwok, K; Nash, P; van der Heijde, D; Zerbini, CAF | 1 |
| Mori, S; Ueki, Y; Yoshitama, T | 1 |
| Contreras-Yáñez, I; Ortiz-Haro, AB; Pascual-Ramos, V; Pérez-Román, DI; Ruiz-Medrano, E | 1 |
| Barroso, NS; Furst, DE; Miller, EZ | 1 |
| An, Y; Kwok, K; Li, G; Li, X; Li, Z; Su, H; Wang, L; Wu, Q; Xu, J; Zheng, Y | 1 |
| Bokarewa, MI; Erlandsson, MC | 1 |
| Dasic, G; Frajzyngier, V; Jones, T; Madsen, A; Rojo, R; Valdez, H | 1 |
| Gladman, D; Mease, P | 1 |
| Arbeit, R; Kanhoush, R; Noell, C | 1 |
| Hider, SL; Scott, DL; Scott, IC | 1 |
| Biswas, P; Brennan, TV; Bukowski, JF; Cheng, J; Clark, JD; Collinge, M; Hammond, C; Hazra, A; Hodge, JA; Jesson, MI; Lan, S; Lin, L; Mojcik, CF; Noveck, RJ; Staats, JS; Stempora, L; Weinhold, KJ; Wouters, A | 1 |
| Bermejo, I; Martyn-St James, M; Ren, S; Scott, DL; Stevenson, M; Uttley, L; Wong, R; Young, A | 1 |
| Abrahamowicz, M; Bernatsky, S; Curtis, JR; Guerra, SF; Machado, MAÁ; Moura, CS | 1 |
| Du, GH; Jian, LL; Li, CH; Liu, XY; Sun, L; Xu, LL; Yu, RH; Zhao, JX | 1 |
| Abe, N; Jodo, S; Kudo, T | 1 |
| Bananis, E; Bergman, MJ; Dikranian, A; Lee, EB; Strand, V; Takiya, L; Wilkinson, B; Yazici, Y; Zang, C | 1 |
| Chapman, D; DeMasi, R; Fallon, L; Keystone, E; Lee, EB; van Vollenhoven, RF; Wilkinson, B; Zwillich, SH | 1 |
| Bodycombe, D; Curtis, JR; Dyagilev, K; Kan, HJ; Kharrazi, H; Molta, CT; Saria, S; Schulam, P | 1 |
| Biniecka, M; Fearon, U; Gallagher, L; Low, C; McGarry, T; Orr, C; Veale, DJ; Wade, S | 1 |
| Bensen, W; Bird, P; El-Zorkany, B; Kaine, J; Manapat-Reyes, BH; Pascual-Ramos, V; Soma, K; Thirunavukkarasu, K; Witcombe, D; Zhang, R | 1 |
| Cho, H; Choy, EH; Hashizume, M; John, MR; O'Mahony, A | 1 |
| Bourret, JA; Claxton, L; Gerber, RA; Soonasra, A; Taylor, M | 1 |
| Yin, Y; Zhang, DY; Zhang, TT | 1 |
| Galdamez, J; Goldring, SR; Lele, SM; Liu, Y; Mikuls, TR; Purdue, PE; Soni, DM; Wang, D; Wang, X; Wei, X; Wu, J; Zhao, G | 1 |
| Claxton, L; Gerber, RA; Gruben, D; Moynagh, D; Singh, A; Taylor, M; Wallenstein, GV | 1 |
| Aguirre-Valencia, D; Naranjo-Escobar, J; Navarro, EP; Posso-Osorio, I; Tobón, GJ | 1 |
| Atzeni, F; Gerratana, E; Marino, F; Masala, IF; Nucera, V; Sangari, D; Sarzi-Puttini, P; Talotta, R | 1 |
| Bastian, Y; Castañeda-Delgado, JE; Castañeda-Sánchez, JJ; Castillo-Ortiz, JD; Enciso-Moreno, JA; Fernández-Ruiz, JC; González-Amaro, R; Monsivais-Urenda, AE; Ochoa-González, F; Ramos-Remus, C; Romo-García, MF; Sánchez-Corona, J | 1 |
| Akylbekova, EL; Brenol, CV; de Leon, DP; García, EG; Lomonte, ABV; Marcolino, FMD; Radominski, SC; Rojo, R; Zerbini, CAF | 1 |
| Chen, C; Deng, C; Fan, H; Lamba, M; Lukic, T; Mojcik, C; Stock, T; Sugiyama, N; Tanaka, Y; Toyoizumi, S; Valdez, H; Yuasa, H; Zhang, R | 1 |
| Dawwas, GK; Thai, TN | 1 |
| Bananis, E; Cohen, S; Connell, CA; Fan, H; Fleischmann, R; Haraoui, B; Kaine, J; Keystone, E; Kivitz, AJ; Takiya, L; van Vollenhoven, RF | 1 |
| Bae, SC; Lee, YH | 2 |
| Chikugo, M; Harada, N; Iuchi, M; KIshi, J; Kuroda, M; Nishioka, Y; Sakaue, H; Sebe, M; Tsutsumi, R | 1 |
| Bernatsky, S; Chen, L; Curtis, JR; Winthrop, K; Xie, F; Yang, S; Yun, H | 1 |
| Gru, AA; Junkins-Hopkins, JM; Williams, E | 1 |
| Bananis, E; Charles-Schoeman, C | 1 |
| Boers, M | 1 |
| Adawi, M; Amital, H; Biln, NK; Blank, M; Bragazzi, NL; Gilburd, B; Katz, I; Langevitz, P; Lidar, M; Marotta, A; Perez, D; Shoenfeld, Y; Shovman, O; Watad, A | 1 |
| An, Y; Bao, CD; Chen, ZW; Gu, JR; Hwang, LJ; Kremer, J; Li, ZG; Liu, Y; Wang, L; Wu, QZ; Xu, HJ; Zhao, DB | 1 |
| Biswas, P; Choy, E; Clark, JD; Hazra, A; Hodge, J; Krishnaswami, S; Lazariciu, I; Lee, EB; Mojcik, C; Strengholt, S; Valdez, H; van Vollenhoven, R; Wang, L | 1 |
| Jia, J; Li, W; Liao, W; Liu, W; Ou, F; Su, K; Sun, J; Sun, Y; Zhang, Z; Zheng, Y | 1 |
| Desai, RJ; Kim, SC; Pawar, A; Weinblatt, ME | 1 |
| Chen, DY; Chen, HH; Chen, JP; Chen, YH; Chen, YM; Hsieh, TY; Huang, WN; Hung, WT; Liao, TL; Yang, SS | 1 |
| Cacciapaglia, F; Fornaro, M; Iannone, F; Lopalco, G; Venerito, V | 1 |
| Deng, W; Sun, L; Wu, Q; Zhang, Z | 1 |
| Bertolo, MB; Brenol, CV; Castelar Pinheiro, GDR; Cruz, BA; de Albuquerque, CP; de Freitas, MVC; Duarte, ALBP; Giorgi, RDN; Gomides, APM; Kakehasi, AM; Laurindo, IMM; Louzada-Júnior, P; Mota, LMHD; Pereira, IA; Ubirajara Silva de Souza, MPG; Xavier, RM | 1 |
| Cardiel, MH; Cohen, S; Connell, CA; Fleischmann, R; Gruben, D; Keystone, E; Kremer, J; Nash, P; Song, YW; Strand, V; Tanaka, Y; Tegzová, D; van der Heijde, D; Wallenstein, G; Zerbini, CAF | 1 |
| Alegre-Del Rey, E; Camean-Castillo, M; Fenix-Caballero, S; Gimeno-Ballester, V; Rios-Sanchez, E; Vázquez-Real, M | 1 |
| De Silva, T; Le Marshall, K; Rischin, A | 1 |
| Westhovens, R | 1 |
| Taylor, PC | 1 |
| Chen, L; He, J; Li, W; Niu, T; Pei, H; Xiang, M; Zhang, C; Zhu, J | 1 |
| Bird, P; Connell, CA; Hall, S; Kwok, K; Nash, P; Thirunavukkarasu, K; Witcombe, D | 1 |
| Chen, C; Kwok, K; Lee, EB; Liu, Y; Llamado, LJ; Luo, Y; Sugiyama, N; Tanaka, Y; Tsai, WC; Wang, L; Yamanaka, H; Yoo, HJ | 1 |
| Cohen, S; Curtis, JR; DeMasi, R; Kwok, K; Lazariciu, I; Lee, EB; Mojcik, C; Silverfield, J; Soma, K; Strengholt, S; Terry, K; Wang, L; Wollenhaupt, J | 1 |
| Atzeni, F; Bechman, K; Cope, AP; Galli, M; Galloway, JB; Norton, S; Subesinghe, S; Winthrop, KL | 1 |
| Aykara, I; Diller, M; Frommer, K; Hasseli, R; Hülser, ML; Müller-Ladner, U; Neumann, E; Rehart, S | 1 |
| Yamaoka, K | 3 |
| Chen, CI; Fournier, M; Gal, P; Kiss, Z; Kuznik, A; Michaud, K; Muszbek, N; Proudfoot, C | 1 |
| Demidova, NV; Kirillova, IG; Markelova, EI; Misiyuk, AS; Novikova, DS; Popkova, TV; Udachkina, HV | 1 |
| Feng, Q; Guo, M; Qiu, Q; Tan, X | 1 |
| Almanzar, G; Kienle, F; Maas, A; Prelog, M; Schmalzing, M; Tony, HP | 1 |
| Gomides, AP; Mota, L; Neto, LL; Rocha Silva, C; Scheinberg, MA; Winthrop, K | 1 |
| Witte, T | 1 |
| Chan, EWY; Li, X; Man, KK; Pathadka, S; Wong, ICK | 1 |
| Choong, K; Dyer, J; Morwood, K | 1 |
| Abud-Mendoza, C; Calabrese, LH; Fleischmann, R; Iikuni, N; Lee, SH; Lindsey, SM; Luo, Z; Soma, K; Takiya, L; Tatulych, S | 1 |
| Choi, SJ; Lee, YH; Song, GG | 1 |
| Bonelli, M; Dalwigk, K; Hayer, S; Holinka, J; Karonitsch, T; Kiener, HP; Niederreiter, B; Olmos Calvo, I; Pap, T; Platzer, A; Sevelda, F; Smolen, JS; Steiner, G; Superti-Furga, G | 1 |
| Almon, RR; DuBois, DC; Jusko, WJ; Song, D; Yu, R | 1 |
| Byers, NL; Higgs, RE; Lee, J; Macias, WL; McInnes, IB; Na, S; Ortmann, RA; Rocha, G; Rooney, TP; Taylor, PC; Wehrman, T; Zhang, X; Zuckerman, SH | 1 |
| Huang, Z; Kane, S; Lissoos, T; Moran, K; Null, K | 1 |
| Biswas, P; Boy, MG; Charles-Schoeman, C; DeMasi, R; Hwang, LJ; McInnes, IB; Soma, K; Valdez, H | 1 |
| Bradley, JD; Brosnan, MJ; Connell, CA; Kim, HY; Lee, SH; Luo, Z; Mandel, D; McInnes, IB; Song, YW; Zuckerman, A; Zwillich, SH | 1 |
| Bannwarth, B; Kostine, M; Poursac, N | 1 |
| Deodhar, A | 1 |
| Koch, S; Peyrin-Biroulet, L; Vuitton, L | 1 |
| Ferraccioli, G; Gremese, E | 1 |
| Benda, B; Bradley, J; Burmester, GR; Gruben, D; Mebus, C | 1 |
| Scott, LJ | 1 |
| Kawalec, P; Mikrut, A; Pilc, A; Wiśniewska, N | 1 |
| Conaghan, PG; Rakieh, C | 1 |
| Choi, IA; Kim, JW; Lee, EB; Lee, EY; Song, YW | 1 |
| Tanaka, Y; Yamaoka, K | 3 |
| Eguchi, K; Izumi, M; Izumi, Y; Jiuchi, Y; Kawakami, A; Kozuru, H; Migita, K; Motokawa, S; Nakamura, M; Nishino, Y; Nonaka, F; Satomura, K; Torigoshi, T | 1 |
| Bradley, J; Fleischmann, R; Genovese, M; Gruben, D; Hall, S; Isaacs, JD; Koncz, T; Kremer, J; Krishnaswami, S; Li, ZG; Martin-Mola, E; Riese, R; Wallenstein, G; Zwillich, SH | 1 |
| Chan, EW; Chui, CS; He, Y; Lau, WC; Man, KK; Wong, AY; Wong, IC; Worsley, AJ | 1 |
| Berhan, A | 1 |
| Bandy, JL; Boyce, EG; O'Dell, KM; Vyas, D | 1 |
| Chen, Y; Liang, F; Shi, P; Wang, Q; Wei, D; Xiao, X; Yao, L; Yin, X; Zhang, X | 1 |
| Buch, MH; Gaujoux-Viala, C; Gossec, L; Landewé, R; Nam, J; Ramiro, S; Smolen, JS | 1 |
| Fukuyo, S; Hirata, S; Kubo, S; Maeshima, K; Saito, K; Sonomoto, K; Suzuki, K; Tanaka, Y; Yamaoka, K | 1 |
| MacFarlane, LA; Todd, DJ | 1 |
| Maneiro, JR; Salgado, E | 1 |
| So, A; Varisco, PA | 1 |
| Izumi, M; Izumi, Y; Jiuchi, Y; Kawahara, C; Kawakami, A; Kozuru, H; Migita, K; Motokawa, S; Nakamura, M; Nakamura, T; Sakai, T | 1 |
| Benda, B; Curtis, JR; Gruben, D; Komuro, Y; Lee, EB; Nakamura, H; Nduaka, CI; Riese, RJ; Silverfield, J; Soma, K; Wang, L; Wollenhaupt, J; Wood, SP; Zwillich, SH | 1 |
| Ikari, K; Inoue, E; Ishida, O; Koenuma, N; Koyama, T; Momohara, S; Ochi, K; Sakuma, Y; Taniguchi, A; Yamanaka, H; Yano, K; Yoshida, S | 1 |
| Dewenter, M; Döker, S; El-Armouche, A | 1 |
| Minota, S | 1 |
| Bradley, JD; Fleischmann, R; Gruben, D; Hall, S; Koncz, T; Krishnaswami, S; Lee, EB; van Vollenhoven, RF; Wallenstein, GV; Wilkinson, B; Zang, C; Zwillich, SH | 1 |
| Chew, R; Kawabata, T; Krishnaswami, S; Mortensen, E; Riese, R; Valdez, H; Winthrop, KL; Yamanaka, H | 1 |
| Benda, B; Cohen, S; Gomez-Reino, JJ; Krishnaswami, S; Kwok, K; Nduaka, CI; Radominski, SC; Riese, R; Soma, K; Valdez, H; Wang, L; Wood, SP | 1 |
| Kalra, S; Kaur, K; Kaushal, S | 1 |
| Boy, MG; Hutmacher, MM; Isaacs, JD; Kowalski, K; Krishnaswami, S; Lan, S; Menon, S; Nduaka, C; Riese, R; Zuckerman, A | 1 |
| Burmester, GR; Gruben, D; Mebus, CA; Strand, V; Wallenstein, GV; Zerbini, CA; Zwillich, SH | 1 |
| Kwok, SK | 1 |
| Bae, SC; Lee, YH; Song, GG | 2 |
| Krishnaswami, S; van Vollenhoven, RF; Wilkinson, B | 1 |
| Sexton, D | 1 |
| Chen, J; Xu, A; Yuan, K | 1 |
| Carmona, L; Gómez-Reino, JJ; Maneiro, JR; Mera, A; Salgado, E; Souto, A | 1 |
| Boyle, DL; Bradley, J; Firestein, GS; Hodge, J; Kaplan, I; Kavanaugh, A; Krishnaswami, S; Luo, Z; Mandel, D; Mease, P; Rosengren, S; Shurmur, R; Singhal, AK; Soma, K; Wei, N | 1 |
| Beysen, C; Charles-Schoeman, C; Davignon, J; Fleischmann, R; Hellerstein, MK; Kaplan, IV; Luo, Z; McInnes, IB; Milad, M; Riese, R; Schwartz, H; Turner, SM; Zuckerman, A | 1 |
| Nakamura, H; Takeuchi, T; Tanaka, Y; Toyoizumi, S; Yamanaka, H; Zwillich, S | 1 |
| Emery, P | 1 |
| Tanaka, Y; Zwillich, SH | 1 |
| Collins, FS; Davis, SR; Erdos, MR; Furumoto, Y; Gadina, M; Jiang, K; Kanno, Y; O'Shea, JJ; Parker, SC; Restifo, NP; Roychoudhuri, R; Ruan, Y; Sartorelli, V; Tang, Z; Vahedi, G | 1 |
| Bingham, CO; Fan, H; Gomez-Reino, J; Hodge, J; Hrycaj, P; Lee, EB; Mebus, C; Neal, J; Racewicz, A; Silverfield, J; Soma, K; Wang, T; Wilkinson, B; Winthrop, KL | 1 |
| Bukowski, J; Hammond, C; Isaacs, JD; Kivitz, AJ; Kremer, JM; Lee, SK; Li, H; Nasonov, EL; Raber, S; Schulman, SL; Simon-Campos, JA; Tony, HP; Vlahos, B; Zuckerman, A | 1 |
| Aungier, SR; Cartwright, AJ; Ito, K; Midwood, KS; To, WS | 1 |
| Benda, B; Curtis, JR; Geier, J; Kaplan, IV; Kwok, K; Lee, EB; Riese, R; Soma, K; Wang, L | 1 |
| Tanaka, Y | 3 |
| Byun, JH; Ko, SK; Lee, EK; Lee, MY; Lee, SM; Park, SK; Park, SY | 1 |
| Bananis, E; Burmester, G; Charles-Schoeman, C; Fleischmann, R; Hendrikx, T; Kwok, K; Nash, P; Soma, K; Zerbini, CA | 1 |
| Cardiel, MH; Gomez-Reino, JJ; Gul, A; Kwok, K; Lukic, T; Mortensen, E; Park, SH; Ponce de Leon, D; Riese, R; Tanaka, Y; Valdez, H; Winthrop, KL | 1 |
| Connell, C; Fleischmann, R; Gruben, D; Kanik, KS; Kremer, J; Strand, V; Wallenstein, G; Zwillich, SH | 1 |
| Abbott, B; Weatherspoon, CA; Weatherspoon, D | 1 |
| Cendón, C; Chang, HD; Di Ceglie, I; Douni, E; Gómez, L; Kamradt, T; Llop-Guevara, A; Madarena, F; Porras, M; Rinotas, V; Román, J; Siracusa, F; van Lent, PL | 1 |
| Ahadieh, S; Boy, M; Checchio, T; French, J; Geier, J; Gómez-Reino, JJ; Hoffman, E; Krishnaswami, S; Menon, S; Riese, R; Strand, V; Tensfeldt, TG | 1 |
| Hirose, T; Morishima, Y; Sugiyama, N; Takeuchi, T; Tanaka, Y; Toyoizumi, S; Yamanaka, H; Yuasa, H; Zwillich, S | 1 |
| Fleischmann, R; Gruben, D; Koncz, T; Lee, EB; Strand, V; van Vollenhoven, RF; Wallenstein, G; Wilkinson, B; Zwillich, SH | 1 |
| Bowes, MA; Bradley, JD; Conaghan, PG; Fuerst, T; Hrycaj, P; Irazoque-Palazuelos, F; Soma, K; Soto-Raices, O; van der Heijde, D; Wilkinson, B; Wu, C; Wyman, BT; Xie, Z; Zhang, R; Østergaard, M | 1 |
| Boy, M; Charles-Schoeman, C; Geier, J; Gonzalez-Gay, MA; Kaplan, I; Luo, Z; Riese, R; Zuckerman, A | 1 |
| Curtis, JR; Gerber, R; Gruben, D; Harnett, J; Koenig, A | 1 |
| Bernatsky, S; Curtis, JR; Winthrop, KL; Xie, F; Yun, H | 1 |
| Sonomoto, K; Tanaka, Y | 1 |
| Archer, TP; Ghosh, S; Moran, GW | 1 |
| Christensen, R; Hossain, A; Kotb, A; Maxwell, LJ; Mudano, AS; Shah, NP; Singh, JA; Tanjong Ghogomu, E; Tugwell, P; Wells, GA | 1 |
| Bernatsky, S; Curtis, JR; Xie, F; Yun, H | 1 |
| Iwata, S; Tanaka, Y | 1 |
| Chen, Y; Clowse, ME; Feldman, SR; Frazier, D; Geier, J; Isaacs, JD; Kimball, AB; Marren, A; Proulx, J; Strand, V; Warren, RB; Xibillé, D | 1 |
| Kawahito, Y | 1 |
| Biswas, P; Genovese, MC; Gruben, D; Jones, TV; Riese, R; Takiya, L; van Vollenhoven, RF; Wang, L; Wilkinson, B; Zwillich, SH | 1 |
| Boy, M; Charles-Schoeman, C; Geier, J; Gonzalez-Gay, MA; Kwok, K; Riese, R; Soma, K; Wicker, P; Zuckerman, A | 1 |
| Fleischmann, R; Gruben, D; Kanik, K; Keystone, E; Koncz, T; Kremer, J; Krishnaswami, S; Tanaka, Y; Wallenstein, G; Wilkinson, B; Zwillich, SH | 1 |
| Anisfeld, A; Chen, C; Chen, Y; Curtis, JR; Geier, J; Krishnaswami, S; Strengholt, S; Zhang, R | 1 |
| Gruben, D; Kremer, JM; Krishnaswami, S; Strand, V; Wallenstein, GV; Zwillich, SH | 1 |
| Iwata, S; Kubo, S; Nakayamada, S; Tanaka, Y | 1 |
| Bourret, JA; Claxton, L; Gerber, RA; Jenks, M; Mendelsohn, AM; Moynagh, D; Singh, A; Taylor, M; Wallenstein, G | 1 |
| Fukui, S; Horai, Y; Ichinose, K; Iwamoto, N; Kawakami, A; Kawashiri, SY; Koga, T; Nakamura, H; Sato, T; Umeda, M | 1 |
| Lam, S | 1 |
| Bananis, E; Connell, CA; Fleischmann, R; Hwang, LJ; Mease, PJ; Schwartzman, S; Soma, K; Takiya, L | 1 |
| Bannert, B; Erlacher, M; Fischer, K; Janowska, I; Kunze, M; Kyburz, D; Lorenzetti, R; Rizzi, M; Staniek, J; Strohmeier, V; Thiel, J; Troilo, A; Venhoff, N; Voll, RE | 1 |
| Hossain, A; Mudano, AS; Singh, JA; Tanjong Ghogomu, E; Tugwell, P; Wells, GA | 1 |
| Chen, C; Gerber, R; Gruben, D; Harnett, J; Koenig, AS | 1 |
| Jansen, JP; Smiechowski, B; Spurden, D; Vieira, MC; Wallenstein, GV; Zwillich, SH | 1 |
| Cohen, SB; Sivaraman, P | 1 |
| Aletaha, D; Gruben, D; Krishnaswami, S; Mebus, C; Smolen, JS; Zwillich, SH | 1 |
| Bliddal, H; Boers, M; Brock, B; Christensen, R; Dossing, A; Eric Furst, D; Heller Asmussen, K; Luta, G; Schjødt Jørgensen, T; Tarp, S; Tarp, U; Thirstrup, S | 1 |
| DeMasi, R; Kwok, K; Nduaka, C; Schulze-Koops, H; Strand, V; Wallenstein, G; Wang, L | 1 |
| Frank-Bertoncelj, M; Gay, S | 1 |
| Charles-Schoeman, C; Cohen, SB; Curtis, JR; DeMasi, R; Geier, J; Kwok, K; Lee, EB; Mariette, X; Nash, P; Riese, R; Tanaka, Y; Thirunavukkarasu, K; Wang, L; Winthrop, KL; Wollenhaupt, J | 1 |
| Alvarez-Moreno, C; Cardiel, MH; Castañeda, OM; Castelli, G; Citera, G; García, EG; Jaller, JJ; Kwok, K; Mysler, E; Ponce de Leon, D; Radominski, SC; Rillo, O; Rojo, R; Romero, FJ; Salinas, A | 1 |
| Danese, S; Olivera, P; Peyrin-Biroulet, L | 1 |
| Chen, L; Coe, J; Curtis, JR; Gal-Levy, R; Higginbotham, P; Nowell, WB; O'Hara, K; Sa'adon, R; Safford, M; Willig, J | 1 |
| Avaragolla, S; Bala, M; Bhalerao, A; Bhuniya, D; De, S; Dhanave, A; Hariharan, N; Jain, V; Joshi, S; Kaduskar, R; Kulkarni, B; Kurhade, S; Madgula, V; Mavinahalli, J; Mengawade, T; Mookhtiar, KA; Nadeem, A; Naik, K; Pathade, V; Petla, R; Raje, AA; Ray, S; Rouduri, S; Salunkhe, V; Tambe, A; Thakkar, M; Umrani, D | 1 |
| Buchbinder, R; Hossain, A; Lopez-Olivo, MA; Maxwell, LJ; Mudano, AS; Singh, JA; Suarez-Almazor, ME; Tanjong Ghogomu, E; Tugwell, P; Wells, GA | 1 |
| Gomez-Reino, JJ; Maneiro, JR; Souto, A | 1 |
| Gharaibeh, M; Incerti, D; Jansen, JP; Kaur, P; MacEwan, JP; Mutebi, A; Peneva, D; Stolshek, B; Strand, V | 1 |
| Ferringer, T; Lountzis, NI; Puri, PK; Tyler, W | 1 |
| Feifel, R; Hawtin, S; Heng, R; Huppertz, C; Koch, G; Moebitz, H; Revesz, L; Scheufler, C; Schlapbach, A; Velcicky, J; Waelchli, R | 1 |
| Kukhrchuk, VV; Nasonov, EL; Novikova, DS; Popkova, TV; Tutunov, VS | 1 |
| Blaschke, S; Guerluek, S; Klinger, HM; Müller, GA; Schwarz, G; Viereck, V | 1 |
| Kameda, H; Takeuchi, T | 1 |
| Hayashi, T; Sumida, T | 1 |
| West, K | 1 |
| Bloom, BJ; Breedveld, FC; Burgos-Vargas, R; Coombs, JH; Fletcher, MP; Gruben, D; Kremer, JM; Krishnaswami, S; Wilkinson, B; Zerbini, CA; Zwillich, SH | 1 |
| Bloom, BJ; Breedveld, FC; Burgos-Vargas, R; Coombs, JH; Fletcher, MP; Gruben, D; Kremer, JM; Wilkinson, B; Zerbini, CA; Zwillich, SH | 1 |
| Hutcheson, J; Perlman, H | 1 |
| Nikitina, NM; Rebrov, AP | 1 |
| French, J; Friberg, LE; Gupta, P; Karlsson, MO; Krishnaswami, S | 1 |
| Chow, V; Cohen, S; Labadie, RR; Wilkinson, B; Zwillich, SH | 1 |
| Opar, A | 1 |
| Ginsberg, MS; Molina, AM; Motzer, RJ | 1 |
| Kremer, J; Krishnaswami, S; Riese, RJ | 1 |
| Barrish, JC; Dodd, JH; Doweyko, AM; Dyckman, AJ; Gillooly, KM; Hynes, J; Kiefer, SE; Kish, KF; Leftheris, K; Li, T; Lin, J; Lin, S; Liu, C; Marathe, PH; McIntyre, KW; McKinnon, M; Newitt, JA; Pitt, S; Sack, JS; Salter-Cid, L; Schieven, GL; Shen, DR; Shuster, DJ; Wityak, J; Wrobleski, ST; Wu, H; Zhang, H; Zhang, RF | 1 |
| Holme, I; Kvien, TK; Pedersen, TR; Semb, AG | 1 |
| El-Barbary, AM; Hamouda, HE; Hussein, MS; Ismail, RG; Rageh, EM; Wagih, AA | 1 |
| Cheng, X; Ding, YJ; Du, R; Jevallee, H; Liao, MY; Liao, YH; Shi, GP; Song, Y; Tang, TT; Xiao, H; Yao, R; Yu, X; Yuan, J; Zhou, ZH | 1 |
| French, JL; Hutmacher, MM; Krishnaswami, S; Menon, S | 1 |
| John, H; Kitas, GD; Toms, TE | 1 |
| Ishibashi, H; Izumi, Y; Jiuchi, Y; Komori, A; Maeda, Y; Migita, K; Miyashita, T; Motokawa, S; Nakamura, M; Torigoshi, T | 1 |
| Garber, K | 2 |
| French, J; Gruben, D; Tan, H; Thomas, N | 1 |
| Ishibashi, H; Izumi, Y; Jiuchi, Y; Kawakami, A; Koga, T; Komori, A; Maeda, Y; Migita, K; Miyashita, T; Motokawa, S; Nakamura, M; Sato, J; Torigoshi, T; Yamasaki, S | 1 |
| Aiba, Y; Ishibashi, H; Izumi, Y; Jiuchi, Y; Kawakami, A; Koga, T; Komori, A; Maeda, Y; Migita, K; Miyashita, T; Nakamura, M; Yamasaki, S | 1 |
| Asakawa, M; Chiba, K; Kawasumi, M; Kobayashi, T; Miyamoto, T; Mori, T; Morioka, H; Toyama, Y; Yoshida, H; Yoshimura, A | 1 |
| Connell, CA; Cutolo, M; Fleischmann, R; Genovese, MC; Gruben, D; Kanik, KS; Krishnaswami, S; Lee, EB; Sadis, S; Wallenstein, G; Wilkinson, BE; Zwillich, SH | 1 |
| Cohen, S; Connell, CA; French, JL; Gomez-Reino, J; Gruben, D; Kanik, KS; Kremer, JM; Krishnaswami, S; Pascual-Ramos, V; Wallenstein, G; Wilkinson, BE; Zwillich, SH | 1 |
| Regens, AL; Yazici, Y | 1 |
| Boyle, DL; Corr, M; Firestein, GS; Rosengren, S | 1 |
| Ohtsuka, T | 1 |
| Maeshima, K; Maeshima, Y; Tanaka, Y; Yamaoka, K | 1 |
| Kubo, S; Maeshima, K; Sonomoto, K; Tanaka, Y; Yamaoka, K | 1 |
| Lomonte, AB; Zerbini, CA | 1 |
| Leonardi, CL | 1 |
| Bradley, JD; Connell, CA; Cush, J; Fleischmann, R; Gruben, D; Kanik, KS; Kremer, J; Schulze-Koops, H; Wallenstein, GV; Zwillich, SH | 1 |
| Bradley, JD; Cohen, S; Fleischmann, R; Forejtova, S; García Meijide, JA; Gruben, D; Koncz, T; Krishnaswami, S; Lee, EB; van Vollenhoven, RF; Wagner, S; Wallenstein, GV; Wilkinson, B; Zwillich, SH | 1 |
| Fox, DA | 1 |
| Choi, J; Kim, JY; Lee, EB; Lee, EY; Lee, YJ; Song, YW; Yoo, HJ | 1 |
| de Lartigue, J | 1 |
| Chan, C; Ivashkiv, LB; Xu, K; Yarilina, A | 1 |
| Heinzl, S | 1 |
| Traynor, K | 1 |
| Steiger, B; Yazici, Y | 1 |
| Miossec, P | 1 |
| Benda, B; Blanco, R; Bradley, J; Burmester, GR; Charles-Schoeman, C; Gruben, D; Koncz, T; Krishnaswami, S; Mebus, C; Soma, K; Wallenstein, G; Wollenhaupt, J; Zerbini, C; Zwillich, SH | 1 |
| van Vollenhoven, RF | 1 |
| Benda, B; Bradley, JD; Cardiel, MH; Cohen, S; Connell, CA; Fleischmann, R; Gruben, D; Keystone, E; Kremer, J; Krishnaswami, S; Nash, P; Song, YW; Tanaka, Y; Tegzová, D; van der Heijde, D; Wallenstein, G; Wyman, BT; Zerbini, C; Zwillich, SH | 1 |
| Reinke, T | 1 |
| Burmester, GR; Feist, E | 1 |
| Hamsten, A; Klareskog, L | 1 |
| Capell, HA; Ford, I; Hampson, R; Madhok, R; McCarey, DW; McInnes, IB; Sattar, N; Scherbakov, O | 1 |
| McColl, G; Van Doornum, S; Wicks, IP | 1 |
| Abe, K; Akasaka, Y; Inoue, H; Sato, T | 1 |
| Harten, SK; Haskard, DO; Johns, M; Kinderlerer, AR; Lidington, EA; Mason, JC; Maxwell, PH; Steinberg, R | 1 |
| Jansen, TL | 1 |
| de Vegvar, HE; Digennaro, C; Higgins, JP; Ho, PP; Kidd, BA; Lee, LY; Robinson, WH; Steinman, L; Tomooka, B | 1 |
| Hampton, T | 1 |
| Ansell, BJ; Charles-Schoeman, C; Fogelman, AM; Furst, DE; Gong, T; Khanna, D; McMahon, M; Park, GS; Paulus, HE; Reddy, ST | 1 |
| Gay, RE; Gay, S; Kurowska-Stolarska, M; Laufer, S; Michel, BA; Neidhart, M; Ospelt, C | 1 |
| Bielinska, A; Gluszko, P | 1 |
| Changelian, PS; Doty, JL; Flanagan, ME; Harris, TM; Kent, CR; Kudlacz, EM; Kuhn, CF; Magnuson, KS; Moshinsky, D; Munchhof, MJ; Perregaux, DG; Sawyer, PS; Sun, J; Whipple, DA | 1 |
| Audoly, L; Changelian, P; Kudlacz, EM; Milici, AJ; Zwillich, S | 1 |
| O'Brien, WM | 1 |
| Fellmann, N | 1 |
| Gumpel, JM; Prouse, PJ; Wilson, AP | 1 |
| Levy, J | 1 |
| di Munno, O; Sarchi, C | 1 |
| Ehrlich, GE | 1 |
| Desiraju, RK; Dromgoole, SH; Furst, DE; Paulus, HE | 1 |
| Balme, HW; Huskisson, EC; Wojtulewski, JA | 1 |
| Grindel, JM | 1 |
| Desiraju, RK; Dromgoole, SH; Furst, DE; Kirschenbaum, MA; Nayak, RK; Paulus, HE | 1 |
| Desiraju, RK; Ng, KT; Sedberry, DC | 1 |
| Chatterjee, GP | 1 |
| Chabot-Fletcher, M; Jackson, JR; Marshall, LA; Roshak, A | 1 |
| Gay, RE; Gay, S; Laufer, S; Neidhart, M; Pataky, F; Tries, S | 1 |
| Cordrey, LJ | 1 |
| Lewis, JR | 1 |
| Iwasaki, Y; Onoda, D; Shiokawa, Y; Yamamoto, M | 1 |
| Perrotta, P; Silvestri, N | 1 |
| Klemp, P; Meyers, OL | 1 |
| Avery, GS; Brogden, RN; Heel, RC; Speight, TM | 1 |
| Ansell, BM; Carter, ME; Gumpel, JM; Meanock, I; Rosenburg, J; Steele, CE | 1 |
| DeGuzmann, R; Gabovitch, E; Love, DW; Saykaly, RJ; Simon, JA | 1 |
| Davis, JD; Pisko, EJ; Ruchte, IR; Struth, AG; Turner, RA | 1 |
| Miller, JL | 1 |
| Grindel, JM; Migdalof, BH; Plostnieks, J | 1 |
| Pavelka, K; Susta, A | 2 |
| Brown, JR; Weir, AB | 1 |
| Scherbel, AL | 1 |
| Joseph, MW; Sakai, J | 1 |
| Paulus, HE; Restivo, C | 1 |
| Madsen, BW; Selley, ML; Thomas, J | 1 |
| Aylward, M; Holly, F; Maddock, J; Parker, RJ; Thomas, SR | 1 |
| Fostiropoulos, G | 1 |
| Remans, J | 2 |
| Vetter, G | 2 |
| Viara, M | 1 |
| Dequeker, J; Goddeeris, T | 1 |
| Carrington, MD; de Salcedo, I; Lemos, MM; Silva, JL | 1 |
| Commandre, F; Viani, JL | 1 |
| Arramon, JY; Laborie, G | 1 |
| Maibach, E | 1 |
| Zarro, VJ | 1 |
| Bain, LS; Collins, RM; el-Ghobarey, AF; Sargent, NW | 1 |
| Bachmann, F; Hartl, W; Stroescu, O | 1 |
| Bonus, L; Gum, OB; Maggio-Cavaliere, MB | 1 |
| Glass, J; Selley, ML; Thomas, J; Triggs, EJ | 1 |
| Biland, L; Duckert, F; Nyman, D; Rüst, O; Thilo, D | 1 |
| Bastin, JM | 1 |
| Gillet, C; Lamberlin, G; Roba, J; Roncucci, R | 1 |
| Biltris, R; Delmeiren, H; Desproges-Gotteron, R; Diverse, P; Gerard, R; Golstein, M; Le Guen, A; Vetter, G; Viara, M | 1 |
| Adair, SF; Bird, HA; Bojar, R; Catalano, MA; Dixon, JS; Hill, J; Liauw, L; Rotman, H; Sussman, H; Traficante, A | 1 |
| Goehrs, HR; Sagraves, R; Waller, ES | 1 |
| Berkowitz, SS; Bernhard, G; Bilka, PJ; Blechman, WJ; Marchesano, JM; Rosenthal, M; Wortham, GF | 1 |
| Brooks, PM; Lee, P; Sturrock, RD; Watkins, CF | 1 |
| Gardocki, JF; Pruss, TP; Wong, S | 1 |
| Campos, V; Evans, EF; Pollack, D; Proctor, JD; Velandia, J; Wasserman, AJ; Wingfield, WL | 1 |
| Balme, HW; Berry, H; Huskisson, EC; Scott, J | 1 |
| Johansson, SV; Strandberg, PO | 1 |
| Iizuka, Y; Masuda, H; Tanaka, K; Tomita, K; Yoshida, N | 1 |
108 review(s) available for pyrroles and Rheumatoid Arthritis
| Article | Year |
|---|---|
Herpes zoster and Janus kinase inhibition in rheumatology and gastroenterology patients: managing risk and vaccination.
Topics: Arthritis, Psoriatic; Arthritis, Rheumatoid; Colitis, Ulcerative; Gastroenterology; Herpes Zoster; Humans; Janus Kinase Inhibitors; Janus Kinases; Pyrroles; Rheumatology; Vaccination | 2022 |
Oral surveillance and JAK inhibitor safety: the theory of relativity.
Topics: Aged; Arthritis, Rheumatoid; Humans; Janus Kinase Inhibitors; Pyrroles; Tumor Necrosis Factor Inhibitors | 2022 |
Real-world evidence of tofacitinib in rheumatoid arthritis patients in Spain.
Topics: Arthritis, Rheumatoid; Female; Humans; Male; Middle Aged; Piperidines; Pyrimidines; Pyrroles; Retrospective Studies; Spain; Treatment Outcome | 2022 |
The Proportion of Patients With Rheumatoid Arthritis Achieving ACR20/50/70; Consistent Patterns of a 60/40/20 as Demonstrated by a Systematic Review and Meta-analysis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Biological Products; Drug Therapy, Combination; Humans; Methotrexate; Pyrroles; Treatment Outcome | 2023 |
Review article: Risk of cardiovascular events in patients with inflammatory bowel disease receiving small molecule drugs.
Topics: Arthritis, Rheumatoid; Bradycardia; Humans; Inflammatory Bowel Diseases; Janus Kinase Inhibitors; Pyrroles | 2023 |
[Role of janus kinase inhibitors in the treatment of rheumatic diseases].
Topics: Antirheumatic Agents; Arthritis, Psoriatic; Arthritis, Rheumatoid; Azetidines; Drug Therapy, Combination; Humans; Janus Kinase Inhibitors; Methotrexate; Piperidines; Purines; Pyrazoles; Pyrimidines; Pyrroles; Sulfonamides; Treatment Outcome | 2019 |
Effect of biologics and targeted synthetic disease-modifying anti-rheumatic drugs on fatigue in rheumatoid arthritis.
Topics: Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Azetidines; Biological Products; Fatigue; Humans; Piperidines; Purines; Pyrazoles; Pyrimidines; Pyrroles; Sulfonamides | 2019 |
Comparison of the efficacy and safety of tofacitinib and filgotinib in patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Bayes Theorem; Drug Therapy, Combination; Humans; Methotrexate; Network Meta-Analysis; Piperidines; Pyridines; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Treatment Outcome; Triazoles | 2020 |
Safety of Janus Kinase Inhibitors in Patients With Inflammatory Bowel Diseases or Other Immune-mediated Diseases: A Systematic Review and Meta-Analysis.
Topics: Arthritis, Rheumatoid; Azetidines; Herpes Zoster; Heterocyclic Compounds, 3-Ring; Humans; Incidence; Inflammatory Bowel Diseases; Janus Kinase Inhibitors; Janus Kinases; Piperidines; Placebos; Psoriasis; Purines; Pyrazoles; Pyridines; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Spondylitis, Ankylosing; Sulfonamides; Survival Analysis; Treatment Outcome; Triazoles | 2020 |
Osteoimmunology in rheumatoid and psoriatic arthritis: potential effects of tofacitinib on bone involvement.
Topics: Arthritis, Psoriatic; Arthritis, Rheumatoid; Bone and Bones; Bone Remodeling; Humans; Immune System; Janus Kinases; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Signal Transduction; STAT Transcription Factors | 2020 |
Comparative Efficacy of JAK Inhibitors for Moderate-To-Severe Rheumatoid Arthritis: A Network Meta-Analysis.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Azetidines; Bayes Theorem; Clinical Trials, Phase III as Topic; Drug Therapy, Combination; Female; Heterocyclic Compounds, 3-Ring; Humans; Janus Kinase Inhibitors; Methotrexate; Network Meta-Analysis; Piperidines; Purines; Pyrazoles; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Severity of Illness Index; Sulfonamides | 2020 |
Comparative efficacy and safety of tofacitinib, baricitinib, upadacitinib, and filgotinib in active rheumatoid arthritis refractory to biologic disease-modifying antirheumatic drugs.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Azetidines; Biological Products; Heterocyclic Compounds, 3-Ring; Humans; Methotrexate; Piperidines; Purines; Pyrazoles; Pyridines; Pyrimidines; Pyrroles; Sulfonamides; Treatment Outcome; Triazoles | 2021 |
JAK inhibitors for the treatment of rheumatoid arthritis.
Topics: Adamantane; Antirheumatic Agents; Arthritis, Rheumatoid; Azetidines; Benzofurans; Cardiovascular Diseases; Herpes Zoster; Humans; Janus Kinases; Molecular Targeted Therapy; Neutropenia; Niacinamide; Piperidines; Protein Kinase Inhibitors; Purines; Pyrazoles; Pyrimidines; Pyrroles; Sulfonamides; Venous Thromboembolism | 2020 |
A case of new-onset vitiligo in a patient on tofacitinib and brief review of paradoxical presentations with other novel targeted therapies.
Topics: Adult; Arthritis, Rheumatoid; Female; Hidradenitis Suppurativa; Humans; Janus Kinase Inhibitors; Keratoacanthoma; Melanoma; Piperidines; Programmed Cell Death 1 Receptor; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Psoriasis; Pyrimidines; Pyrroles; Tumor Necrosis Factor-alpha; Vitiligo | 2020 |
Cost-Effectiveness of Tofacitinib for Patients with Moderate-to-Severe Rheumatoid Arthritis in China.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; China; Cost-Benefit Analysis; Humans; Methotrexate; Piperidines; Pyrimidines; Pyrroles; Quality-Adjusted Life Years; Treatment Outcome | 2020 |
Comparison of the efficacy and safety of tofacitinib and mavrilimumab in patients with active rheumatoid arthritis: A Bayesian network meta-analysis of randomized controlled trials.
Topics: Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Humans; Methotrexate; Network Meta-Analysis; Piperidines; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Treatment Outcome | 2021 |
Early phase studies of JAK1 selective inhibitors in rheumatoid arthritis.
Topics: Acetonitriles; Arthritis, Rheumatoid; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Heterocyclic Compounds, 3-Ring; Humans; Janus Kinase 1; Janus Kinase Inhibitors; Pyrazoles; Pyridines; Pyrimidines; Pyrroles; Triazoles | 2021 |
Tofacitinib in the Treatment of Rheumatoid Arthritis and Chronic Plaque Psoriasis.
Topics: Arthritis, Rheumatoid; Clinical Trials, Phase III as Topic; Humans; Janus Kinase 3; Piperidines; Protein Kinase Inhibitors; Psoriasis; Pyrimidines; Pyrroles; Treatment Outcome | 2017 |
Efficacy of glucocorticoids, conventional and targeted synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Azetidines; Drug Therapy, Combination; Glucocorticoids; Humans; Methotrexate; Piperidines; Practice Guidelines as Topic; Purines; Pyrazoles; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Sulfonamides | 2017 |
Biologics or tofacitinib for people with rheumatoid arthritis naive to methotrexate: a systematic review and network meta-analysis.
Topics: Abatacept; Adalimumab; Adult; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Bayes Theorem; Biological Products; Etanercept; Humans; Infliximab; Methotrexate; Methylprednisolone; Network Meta-Analysis; Piperidines; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rituximab | 2017 |
2017 American College of Rheumatology/American Association of Hip and Knee Surgeons Guideline for the Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty.
Topics: Antirheumatic Agents; Arthritis, Juvenile; Arthritis, Psoriatic; Arthritis, Rheumatoid; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Elective Surgical Procedures; Glucocorticoids; Humans; Lupus Erythematosus, Systemic; Perioperative Care; Piperidines; Pyrimidines; Pyrroles; Rheumatic Diseases; Rheumatology; Spondylarthritis; Spondylitis, Ankylosing; Surgeons; United States | 2017 |
Systematic Literature Review and Meta-analysis of Tumor Necrosis Factor-Alpha Experienced Rheumatoid Arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Biological Products; Humans; Piperidines; Pyrimidines; Pyrroles; Treatment Outcome; Tumor Necrosis Factor-alpha | 2017 |
A review of tofacitinib efficacy in rheumatoid arthritis patients who have had an inadequate response or intolerance to methotrexate.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Humans; Janus Kinase Inhibitors; Methotrexate; Piperidines; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Treatment Outcome | 2017 |
Two new drugs for rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Azetidines; Humans; Piperidines; Purines; Pyrazoles; Pyrimidines; Pyrroles; Sulfonamides | 2017 |
Tofacitinib in the treatment of active rheumatoid arthritis in adults.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Clinical Trials as Topic; Drug Approval; Drug Therapy, Combination; Humans; Janus Kinases; Molecular Targeted Therapy; Piperidines; Pyrimidines; Pyrroles | 2018 |
[Inhibition of the Janus kinase-signal transducer and activator of transcription is a new treatment modality of rheumatoid arthritis].
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Azetidines; Herpes Zoster; Humans; Janus Kinase Inhibitors; Piperidines; Protein Kinase Inhibitors; Purines; Pyrazoles; Pyrimidines; Pyrroles; Sulfonamides | 2017 |
Tofacitinib: A Review in Rheumatoid Arthritis.
Topics: Adalimumab; Antirheumatic Agents; Arthritis, Rheumatoid; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Janus Kinases; Methotrexate; Piperidines; Pyrimidines; Pyrroles | 2017 |
Thromboembolism with Janus Kinase (JAK) Inhibitors for Rheumatoid Arthritis: How Real is the Risk?
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Azetidines; Clinical Trials as Topic; Humans; Janus Kinase Inhibitors; Piperidines; Purines; Pyrazoles; Pyrimidines; Pyrroles; Risk Factors; Sulfonamides; Thromboembolism | 2018 |
Tofacitinib for Treating Rheumatoid Arthritis After the Failure of Disease-Modifying Anti-rheumatic Drugs: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Cost-Benefit Analysis; Drug Costs; Drug Resistance; Drug Therapy, Combination; Humans; Methotrexate; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Quality-Adjusted Life Years; Technology Assessment, Biomedical | 2018 |
Tofacitinib 5 mg Twice Daily in Patients with Rheumatoid Arthritis and Inadequate Response to Disease-Modifying Antirheumatic Drugs: A Comprehensive Review of Phase 3 Efficacy and Safety.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Clinical Trials, Phase III as Topic; Humans; Janus Kinase Inhibitors; Piperidines; Pyrimidines; Pyrroles; Treatment Outcome | 2019 |
[Research progress of JAK-3 kinase and its inhibitors].
Topics: Arthritis, Rheumatoid; Humans; Janus Kinase 3; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles | 2016 |
Adverse events, clinical considerations and management recommendations in rheumatoid arthritis patients treated with JAK inhibitors.
Topics: Animals; Antirheumatic Agents; Arthritis, Rheumatoid; Azetidines; Clinical Trials as Topic; Humans; Janus Kinase 1; Piperidines; Purines; Pyrazoles; Pyrimidines; Pyrroles; Sulfonamides | 2018 |
Comparison of the efficacy and safety of tofacitinib and baricitinib in patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Azetidines; Bayes Theorem; Humans; Network Meta-Analysis; Piperidines; Purines; Pyrazoles; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Sulfonamides | 2019 |
Clinical significance of Janus Kinase inhibitor selectivity.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Azetidines; Humans; Inflammation; Janus Kinase Inhibitors; Piperidines; Purines; Pyrazoles; Pyrimidines; Pyrroles; Sulfonamides | 2019 |
A Bayesian mixed treatment comparison of efficacy of biologics and small molecules in early rheumatoid arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Bayes Theorem; Biological Factors; Drug Therapy, Combination; Etanercept; Humans; Infliximab; Methotrexate; Network Meta-Analysis; Piperidines; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rituximab; Treatment Outcome | 2019 |
Tuberculosis, hepatitis B and herpes zoster in tofacitinib-treated patients with rheumatoid arthritis.
Topics: Animals; Antirheumatic Agents; Arthritis, Rheumatoid; Asia, Eastern; Drug Therapy, Combination; Herpes Zoster; Herpesvirus 3, Human; Humans; Mycobacterium tuberculosis; Piperidines; Prevalence; Pyrimidines; Pyrroles; Recurrence; Risk; Tuberculosis; Virus Activation | 2019 |
Network meta-analysis of tofacitinib versus biologic treatments in moderate-to-severe rheumatoid arthritis patients.
Topics: Arthritis, Rheumatoid; Biological Products; Humans; Network Meta-Analysis; Piperidines; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic | 2019 |
Clinical efficacy of new JAK inhibitors under development. Just more of the same?
Topics: Adamantane; Arthritis, Rheumatoid; Azetidines; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, 3-Ring; Humans; Janus Kinase 1; Janus Kinase 3; Janus Kinase Inhibitors; Niacinamide; Piperidines; Purines; Pyrazoles; Pyridines; Pyrimidines; Pyrroles; Sulfonamides; Treatment Outcome; Triazoles; Valine | 2019 |
Clinical efficacy of launched JAK inhibitors in rheumatoid arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Azetidines; Drug Therapy, Combination; Humans; Janus Kinase 1; Janus Kinase 2; Janus Kinase 3; Janus Kinase Inhibitors; Methotrexate; Piperidines; Purines; Pyrazoles; Pyrimidines; Pyrroles; Sulfonamides; Treatment Outcome | 2019 |
A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Azetidines; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Female; Herpes Zoster; Heterocyclic Compounds, 3-Ring; Humans; Incidence; Infections; Janus Kinase Inhibitors; Male; Middle Aged; Piperidines; Purines; Pyrazoles; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Sulfonamides | 2019 |
Tofacitinib for the treatment of rheumatoid arthritis: an update.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Humans; Methotrexate; Piperidines; Pyrimidines; Pyrroles | 2019 |
JAK3-selective inhibitor peficitinib for the treatment of rheumatoid arthritis.
Topics: Adamantane; Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Cell Proliferation; Humans; Janus Kinase 3; Janus Kinase Inhibitors; Methotrexate; Niacinamide; Piperidines; Pyrimidines; Pyrroles | 2019 |
[JAK Inhibitors in Rheumatology].
Topics: Arthritis, Rheumatoid; Azetidines; Germany; Humans; Janus Kinase Inhibitors; Piperidines; Purines; Pyrazoles; Pyrimidines; Pyrroles; Sulfonamides | 2019 |
Comparison of the efficacy and safety of tofacitinib and upadacitinib in patients with active rheumatoid arthritis: A Bayesian network meta-analysis of randomized controlled trials.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Bayes Theorem; Drug Therapy, Combination; Heterocyclic Compounds, 3-Ring; Humans; Janus Kinase Inhibitors; Methotrexate; Network Meta-Analysis; Piperidines; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Treatment Outcome | 2019 |
A pharmacokinetic and clinical assessment of tofacitinib for the treatment of rheumatoid arthritis.
Topics: Administration, Oral; Animals; Antirheumatic Agents; Arthritis, Rheumatoid; Cytochrome P-450 CYP3A; Humans; Janus Kinase 1; Janus Kinase 3; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles | 2013 |
Janus kinase inhibition with tofacitinib: changing the face of inflammatory bowel disease treatment.
Topics: Arthritis, Rheumatoid; Clinical Trials as Topic; Colitis, Ulcerative; Crohn Disease; Humans; Immunosuppression Therapy; Immunosuppressive Agents; Inflammatory Bowel Diseases; Janus Kinases; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; United States; United States Food and Drug Administration | 2013 |
Tofacitinib: a review of its use in adult patients with rheumatoid arthritis.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Treatment Outcome | 2013 |
The effectiveness of tofacitinib, a novel Janus kinase inhibitor, in the treatment of rheumatoid arthritis: a systematic review and meta-analysis.
Topics: Adalimumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Inflammation; Janus Kinases; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Risk; Treatment Outcome; Tumor Necrosis Factor-alpha | 2013 |
Tofacitinib for treatment of rheumatoid arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Janus Kinase 3; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Treatment Outcome | 2013 |
[JAK inhibitor].
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Janus Kinases; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Signal Transduction | 2013 |
Efficacy and safety of tofacitinib in the treatment of rheumatoid arthritis: a systematic review and meta-analysis.
Topics: Adalimumab; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Janus Kinase 3; Piperidines; Pyrimidines; Pyrroles; Treatment Outcome | 2013 |
Targeting the Janus kinases in rheumatoid arthritis: focus on tofacitinib.
Topics: Animals; Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Janus Kinases; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles | 2014 |
Efficacy, safety and tolerability of tofacitinib in patients with an inadequate response to disease modifying anti-rheumatic drugs: a meta-analysis of randomized double-blind controlled studies.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Double-Blind Method; Humans; Piperidines; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Treatment Failure | 2013 |
Tofacitinib: The First Janus Kinase (JAK) inhibitor for the treatment of rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Aryl Hydrocarbon Hydroxylases; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP3A; Dose-Response Relationship, Drug; Drug Interactions; Humans; Janus Kinases; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Treatment Outcome | 2013 |
Tofacitinib for acute rheumatoid arthritis patients who have had an inadequate response to disease-modifying antirheumatic drug (DMARD): a systematic review and meta-analysis.
Topics: Acute Disease; Antirheumatic Agents; Arthritis, Rheumatoid; Biological Products; Female; Humans; Male; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Remission Induction; Treatment Outcome | 2014 |
Efficacy of conventional synthetic disease-modifying antirheumatic drugs, glucocorticoids and tofacitinib: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Evidence-Based Medicine; Glucocorticoids; Humans; Methotrexate; Piperidines; Practice Guidelines as Topic; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Treatment Outcome | 2014 |
Kinase inhibitors: the next generation of therapies in the treatment of rheumatoid arthritis.
Topics: Animals; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Design; Humans; Janus Kinases; Molecular Targeted Therapy; Piperidines; Protein Kinase Inhibitors; Protein Kinases; Pyrimidines; Pyrroles; Signal Transduction | 2014 |
[New therapies for rheumatoid arthritis].
Topics: Abatacept; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Piperidines; Pyrimidines; Pyrroles; Rituximab; Treatment Outcome; Tumor Necrosis Factor-alpha | 2014 |
Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, for the treatment of rheumatoid arthritis in open-label, longterm extension studies.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Female; Humans; Janus Kinase 3; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles | 2014 |
[Tofacitinib].
Topics: Administration, Oral; Arthritis, Rheumatoid; Clinical Trials, Phase III as Topic; Drug Approval; Europe; Humans; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Treatment Outcome | 2014 |
Analysis of infections and all-cause mortality in phase II, phase III, and long-term extension studies of tofacitinib in patients with rheumatoid arthritis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Female; Humans; Infections; Longitudinal Studies; Male; Methotrexate; Middle Aged; Piperidines; Prevalence; Proportional Hazards Models; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Retrospective Studies; Risk Factors; Survival Rate; Treatment Outcome; Young Adult | 2014 |
Systematic review of tofacitinib: a new drug for the management of rheumatoid arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Methotrexate; Piperidines; Pyrimidines; Pyrroles; Treatment Outcome | 2014 |
Efficacy and safety of tofacitinib for active rheumatoid arthritis with an inadequate response to methotrexate or disease-modifying antirheumatic drugs: a meta-analysis of randomized controlled trials.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Humans; Janus Kinases; Methotrexate; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Treatment Outcome | 2014 |
Lipid profile changes in patients with chronic inflammatory arthritis treated with biologic agents and tofacitinib in randomized clinical trials: a systematic review and meta-analysis.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Arthritis, Rheumatoid; Biological Products; Chronic Disease; Female; Humans; Lipids; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Spondylarthritis; Treatment Outcome | 2015 |
Tofacitinib, an oral Janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical development programme.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dose-Response Relationship, Drug; Female; Humans; Incidence; Janus Kinase 3; Male; Middle Aged; Multicenter Studies as Topic; Neoplasms; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Young Adult | 2016 |
Comparative efficacy and safety of tofacitinib, with or without methotrexate, in patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Bayes Theorem; Drug Therapy, Combination; Humans; Methotrexate; Piperidines; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Treatment Outcome | 2015 |
Recent progress and perspective in JAK inhibitors for rheumatoid arthritis: from bench to bedside.
Topics: Arthritis, Rheumatoid; Humans; Inflammation; Janus Kinase 1; Janus Kinase 3; Methotrexate; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; STAT1 Transcription Factor; Translational Research, Biomedical; Tumor Necrosis Factor-alpha | 2015 |
Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Clinical Trials as Topic; Humans; Immunocompromised Host; Immunosuppressive Agents; Incidence; Janus Kinase 3; Opportunistic Infections; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Risk Assessment; Tuberculosis | 2016 |
Pharmacology Update on Chronic Obstructive Pulmonary Disease, Rheumatoid Arthritis, and Major Depression.
Topics: Anti-Anxiety Agents; Arthritis, Rheumatoid; Benzyl Alcohols; Bronchodilator Agents; Chlorobenzenes; Depressive Disorder; Fluticasone; Humans; Nursing Process; Piperazines; Piperidines; Protein Kinase Inhibitors; Pulmonary Disease, Chronic Obstructive; Pyrimidines; Pyrroles; Sulfides; United States; Vortioxetine | 2015 |
Systematic review and meta-analysis of serious infections with tofacitinib and biologic disease-modifying antirheumatic drug treatment in rheumatoid arthritis clinical trials.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Biological Products; Communicable Diseases; Humans; Janus Kinase 3; Piperidines; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Treatment Outcome | 2015 |
Comparative efficacy and safety of tocilizumab, rituximab, abatacept and tofacitinib in patients with active rheumatoid arthritis that inadequately responds to tumor necrosis factor inhibitors: a Bayesian network meta-analysis of randomized controlled tri
Topics: Abatacept; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Bayes Theorem; Biological Products; Drug Substitution; Humans; Network Meta-Analysis; Odds Ratio; Piperidines; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rituximab; Treatment Failure; Tumor Necrosis Factor-alpha | 2016 |
Effects of tofacitinib and other DMARDs on lipid profiles in rheumatoid arthritis: implications for the rheumatologist.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Lipids; Piperidines; Pyrimidines; Pyrroles; Rheumatology | 2016 |
Relevance of involvement of tofacitinib in T cell subsets to clinical courses and adverse events in patients with rheumatoid arthritis.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Female; Herpes Zoster; Humans; Janus Kinases; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; T-Lymphocyte Subsets | 2015 |
Tofacitinib in ulcerative colitis.
Topics: Animals; Arthritis, Rheumatoid; Autoimmunity; Colitis, Ulcerative; Cytokines; Humans; Janus Kinases; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Signal Transduction | 2016 |
Biologics or tofacitinib for rheumatoid arthritis in incomplete responders to methotrexate or other traditional disease-modifying anti-rheumatic drugs: a systematic review and network meta-analysis.
Topics: Adalimumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Biological Products; Certolizumab Pegol; Etanercept; Humans; Infliximab; Interleukin 1 Receptor Antagonist Protein; Methotrexate; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rituximab | 2016 |
Benefit and Risk of Tofacitinib in the Treatment of Rheumatoid Arthritis: A Focus on Herpes Zoster.
Topics: Animals; Antirheumatic Agents; Arthritis, Rheumatoid; Herpes Zoster; Humans; Janus Kinases; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles | 2016 |
Progress in understanding the safety and efficacy of Janus kinase inhibitors for treatment of rheumatoid arthritis.
Topics: Administration, Oral; Animals; Antirheumatic Agents; Arthritis, Rheumatoid; Azetidines; Clinical Trials as Topic; Heterocyclic Compounds, 2-Ring; Humans; Janus Kinase 1; Piperidines; Protein Kinase Inhibitors; Purines; Pyrazoles; Pyrimidines; Pyrroles; Sulfonamides; Treatment Outcome; Valine | 2016 |
[Guidelines for the management of rheumatoid arthritis].
Topics: Abatacept; Algorithms; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Biological Products; Drug Substitution; Drug Therapy, Combination; Humans; Japan; Methotrexate; Piperidines; Practice Guidelines as Topic; Pyrimidines; Pyrroles | 2016 |
[Tofacitinib for the treatment of rheumatoid arthritis].
Topics: Administration, Ophthalmic; Antirheumatic Agents; Arthritis, Rheumatoid; Azetidines; Clinical Trials as Topic; Drug Discovery; Humans; Janus Kinases; Lymphocytes; Molecular Targeted Therapy; Piperidines; Purines; Pyrazoles; Pyrimidines; Pyrroles; Signal Transduction; Sulfonamides; Treatment Outcome | 2016 |
Relation between disease modifying anti-rheumatic drugs and herpes zoster in rheumatoid arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Follow-Up Studies; Herpes Zoster; Humans; Incidence; Janus Kinases; Japan; Molecular Targeted Therapy; Piperidines; Product Surveillance, Postmarketing; Pyrimidines; Pyrroles | 2016 |
Efficacy and safety of tofacitinib in patients with active rheumatoid arthritis: review of key Phase 2 studies.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Clinical Trials, Phase II as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Janus Kinases; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Remission Induction; Treatment Outcome | 2016 |
Recent Progress in JAK Inhibitors for the Treatment of Rheumatoid Arthritis.
Topics: Animals; Antirheumatic Agents; Arthritis, Rheumatoid; Azetidines; Heterocyclic Compounds, 3-Ring; Humans; Janus Kinases; Molecular Targeted Therapy; Piperidines; Protein Kinase Inhibitors; Purines; Pyrazoles; Pyridines; Pyrimidines; Pyrroles; Sulfonamides; Triazoles | 2016 |
Biologic or tofacitinib monotherapy for rheumatoid arthritis in people with traditional disease-modifying anti-rheumatic drug (DMARD) failure: a Cochrane Systematic Review and network meta-analysis (NMA).
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Biological Products; Certolizumab Pegol; Disease Progression; Etanercept; Humans; Interleukin 1 Receptor Antagonist Protein; Methotrexate; Network Meta-Analysis; Piperidines; Pyrimidines; Pyrroles; Rituximab; Treatment Failure | 2016 |
Tofacitinib Versus Biologic Treatments in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Tumor Necrosis Factor Inhibitors: Results From a Network Meta-analysis.
Topics: Abatacept; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Biological Products; Drug Therapy, Combination; Humans; Male; Methotrexate; Network Meta-Analysis; Piperidines; Pyrimidines; Pyrroles; Rituximab; Treatment Failure; Treatment Outcome; Tumor Necrosis Factor-alpha | 2016 |
Malignancy and Janus Kinase Inhibition.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Incidence; Janus Kinases; Neoplasms; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Skin Neoplasms | 2017 |
Risk of serious adverse effects of biological and targeted drugs in patients with rheumatoid arthritis: a systematic review meta-analysis.
Topics: Abatacept; Adalimumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Biological Products; Certolizumab Pegol; Etanercept; Humans; Network Meta-Analysis; Piperidines; Poisson Distribution; Pyrimidines; Pyrroles; Regression Analysis; Risk; Rituximab | 2017 |
JAK inhibition in inflammatory bowel disease.
Topics: Animals; Arthritis, Rheumatoid; Clinical Trials as Topic; Humans; Inflammatory Bowel Diseases; Janus Kinases; Molecular Targeted Therapy; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Risk Assessment; Signal Transduction; STAT Transcription Factors | 2017 |
Biologics or tofacitinib for people with rheumatoid arthritis unsuccessfully treated with biologics: a systematic review and network meta-analysis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Bayes Theorem; Biological Products; Disease Progression; Humans; Methotrexate; Neoplasms; Network Meta-Analysis; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Treatment Failure | 2017 |
Risks of malignancies related to tofacitinib and biological drugs in rheumatoid arthritis: Systematic review, meta-analysis, and network meta-analysis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Biological Products; Humans; Neoplasms; Network Meta-Analysis; Piperidines; Pyrimidines; Pyrroles; Risk | 2017 |
[Rheumatoid arthritis].
Topics: Abatacept; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Arthritis, Rheumatoid; Autoantibodies; Cytokines; Humans; Immunoconjugates; Janus Kinase 3; Peptides, Cyclic; Piperidines; Pyrimidines; Pyrroles; T-Lymphocyte Subsets; T-Lymphocytes, Regulatory | 2009 |
[Targeted therapies including monoclonal antibodies for connective tissue diseases].
Topics: Adalimumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Arthritis, Rheumatoid; B-Lymphocytes; Connective Tissue Diseases; Etanercept; Humans; Immunoglobulin G; Infliximab; Janus Kinase 3; Piperidines; Pyrimidines; Pyrroles; Receptors, Interleukin-6; Receptors, Tumor Necrosis Factor; Tumor Necrosis Factor-alpha | 2009 |
CP-690550, a JAK3 inhibitor as an immunosuppressant for the treatment of rheumatoid arthritis, transplant rejection, psoriasis and other immune-mediated disorders.
Topics: Animals; Arthritis, Rheumatoid; Clinical Trials as Topic; Drug Evaluation, Preclinical; Graft Rejection; Humans; Immunosuppressive Agents; Janus Kinase 3; Piperidines; Protein Kinase Inhibitors; Psoriasis; Pyrimidines; Pyrroles | 2009 |
BH3-only proteins in rheumatoid arthritis: potential targets for therapeutic intervention.
Topics: Animals; Antirheumatic Agents; Apoptosis; Apoptosis Regulatory Proteins; Arthritis, Rheumatoid; Autoimmunity; Bcl-2-Like Protein 11; BH3 Interacting Domain Death Agonist Protein; Drug Delivery Systems; Drug Design; Gene Expression Regulation; Humans; Indoles; Macrophages; Membrane Proteins; Mice; Mice, Inbred C57BL; Protein Structure, Tertiary; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Pyrroles; Structure-Activity Relationship; T-Lymphocyte Subsets | 2008 |
Inhibition of JAK kinases in patients with rheumatoid arthritis: scientific rationale and clinical outcomes.
Topics: Animals; Antirheumatic Agents; Arthritis, Rheumatoid; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Disease Models, Animal; Drug Therapy, Combination; Enzyme Inhibitors; Health Status; Humans; Janus Kinase 3; Methotrexate; Piperidines; Pyrimidines; Pyrroles; Severity of Illness Index; Treatment Outcome | 2010 |
Rheumatoid arthritis: is it a coronary heart disease equivalent?
Topics: Anticholesteremic Agents; Arthritis, Rheumatoid; Atorvastatin; Coronary Disease; Diabetes Complications; Diabetes Mellitus, Type 2; Heptanoic Acids; Humans; Hyperlipidemias; Pyrroles; Risk Factors | 2011 |
Promising new treatments for rheumatoid arthritis - the kinase inhibitors.
Topics: Aminopyridines; Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Intracellular Signaling Peptides and Proteins; Janus Kinases; Morpholines; Oxazines; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Syk Kinase; Treatment Outcome | 2011 |
[Recent progress in the treatment of rheumatoid arthritis].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Denosumab; Etanercept; Humans; Immunoglobulin G; Infliximab; Interleukin-6; Methotrexate; Molecular Targeted Therapy; Piperidines; Pyrimidines; Pyrroles; RANK Ligand; Receptors, Tumor Necrosis Factor; Reference Standards; Remission Induction; Tumor Necrosis Factor-alpha | 2012 |
Novel small-molecular therapeutics for rheumatoid arthritis.
Topics: Aminopyridines; Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Janus Kinases; Molecular Targeted Therapy; Morpholines; Oxazines; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles | 2012 |
Tofacitinib for the treatment of rheumatoid arthritis.
Topics: Animals; Antirheumatic Agents; Arthritis, Rheumatoid; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Humans; Janus Kinase 3; Piperidines; Pyrimidines; Pyrroles; Treatment Outcome | 2012 |
[Janus kinase inhibitors as a new therapeutic principle].
Topics: Arthritis, Rheumatoid; Colitis, Ulcerative; Enzyme Inhibitors; Humans; Janus Kinases; Nitriles; Piperidines; Primary Myelofibrosis; Pyrazoles; Pyrimidines; Pyrroles; Signal Transduction | 2012 |
JAK inhibitor tofacitinib for treating rheumatoid arthritis: from basic to clinical.
Topics: Animals; Antirheumatic Agents; Arthritis, Rheumatoid; Dose-Response Relationship, Drug; Humans; Janus Kinase 3; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Treatment Outcome | 2013 |
Kinase inhibitors for the treatment of rheumatoid arthritis.
Topics: Aminopyridines; Animals; Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Morpholines; Oxazines; Piperidines; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Signal Transduction; Treatment Outcome | 2012 |
Tofacitinib (Xeljanz) for rheumatoid arthritis.
Topics: Animals; Arthritis, Rheumatoid; Humans; Janus Kinase 3; Piperidines; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic | 2013 |
Rheumatoid arthritis in 2012: Progress in RA genetics, pathology and therapy.
Topics: Arthritis, Rheumatoid; Disease Management; Enzyme Inhibitors; Genetic Predisposition to Disease; HLA Antigens; Humans; Piperidines; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles | 2013 |
Small molecules targeting JAKs--a new approach in the treatment of rheumatoid arthritis.
Topics: Administration, Oral; Aminopyridines; Antirheumatic Agents; Arthritis, Rheumatoid; Clinical Trials, Phase III as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Forecasting; Germany; Humans; Janus Kinases; Male; Maximum Tolerated Dose; Molecular Targeted Therapy; Morpholines; Oxazines; Piperidines; Prognosis; Pyridines; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Severity of Illness Index; Treatment Outcome | 2013 |
[Statins--are they potentially useful in rheumatology?].
Topics: Arthritis, Rheumatoid; Atorvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lupus Erythematosus, Systemic; Osteoporosis; Pyrroles; Rheumatic Diseases; Simvastatin; Treatment Outcome | 2007 |
The pharmacokinetic and metabolic profile of the antiinflammatory agent tolmetin in laboratory animals and man.
Topics: Animals; Arthritis, Experimental; Arthritis, Rheumatoid; Biological Availability; Guinea Pigs; Humans; Kinetics; Mice; Pyrroles; Rats; Species Specificity; Tissue Distribution; Tolmetin | 1981 |
Tolmetin: a review of its pharmacological properties and therapeutic efficacy in rheumatic diseases.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Juvenile; Arthritis, Rheumatoid; Blood Platelets; Endocrine Glands; Humans; Intestinal Absorption; Intestinal Mucosa; Kinetics; Osteoarthritis; Prostaglandin Antagonists; Pyrroles; Rats; Rheumatic Diseases; Skin Tests; Spondylitis, Ankylosing; Tolmetin | 1978 |
102 trial(s) available for pyrroles and Rheumatoid Arthritis
| Article | Year |
|---|---|
Tofacitinib and risk of cardiovascular outcomes: results from the Safety of TofAcitinib in Routine care patients with Rheumatoid Arthritis (STAR-RA) study.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Piperidines; Pyrimidines; Pyrroles; Treatment Outcome; Tumor Necrosis Factor Inhibitors | 2022 |
Impact of Tofacitinib on Components of the ACR Response Criteria: Post Hoc Analysis of Phase III and Phase IIIb/IV Trials.
Topics: Adalimumab; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Humans; Methotrexate; Piperidines; Pyrimidines; Pyrroles; Rheumatology; Treatment Outcome; United States | 2022 |
The impact of tofacitinib on fatigue, sleep, and health-related quality of life in patients with rheumatoid arthritis: a post hoc analysis of data from Phase 3 trials.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Fatigue; Humans; Methotrexate; Piperidines; Pyrimidines; Pyrroles; Quality of Life; Sleep; Treatment Outcome | 2022 |
Efficacy of tofacitinib in patients with rheumatoid arthritis stratified by baseline body mass index: an analysis of pooled data from phase 3 studies.
Topics: Adult; Arthritis, Rheumatoid; Body Mass Index; Humans; Piperidines; Pyrimidines; Pyrroles | 2022 |
Infections in patients with rheumatoid arthritis receiving tofacitinib versus tumour necrosis factor inhibitors: results from the open-label, randomised controlled ORAL Surveillance trial.
Topics: Analgesics, Opioid; Antirheumatic Agents; Arthritis, Rheumatoid; C-Reactive Protein; Female; Humans; Lung Diseases; Piperidines; Pyrimidines; Pyrroles; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha | 2022 |
Biomarkers to predict risk of venous thromboembolism in patients with rheumatoid arthritis receiving tofacitinib or tumour necrosis factor inhibitors.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Biomarkers; Humans; Prospective Studies; Proteomics; Pyrroles; Tumor Necrosis Factor Inhibitors; Venous Thromboembolism | 2022 |
Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: results from the open-label, randomised controlled ORAL Surveillance trial.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Lung Neoplasms; Pyrroles; Risk Factors; Skin Neoplasms; Treatment Outcome; Tumor Necrosis Factor Inhibitors | 2023 |
The effect of tofacitinib on residual pain in patients with rheumatoid arthritis and psoriatic arthritis.
Topics: Adalimumab; Arthritis, Psoriatic; Arthritis, Rheumatoid; Bayes Theorem; C-Reactive Protein; Humans; Inflammation; Pyrroles; Treatment Outcome | 2022 |
Continuation, reduction, or withdrawal of tofacitinib in patients with rheumatoid arthritis achieving sustained disease control: a multicenter, open-label, randomized controlled trial.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; China; Humans; Piperidines; Pyrroles; Quality of Life; Treatment Outcome | 2023 |
Anti-GM-CSF otilimab versus tofacitinib or placebo in patients with active rheumatoid arthritis and an inadequate response to conventional or biologic DMARDs: two phase 3 randomised trials (contRAst 1 and contRAst 2).
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Biological Products; Double-Blind Method; Humans; Methotrexate; Pyrroles; Randomized Controlled Trials as Topic; Treatment Outcome | 2023 |
Very early MRI responses to therapy as a predictor of later radiographic progression in early rheumatoid arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Magnetic Resonance Imaging; Male; Methotrexate; Piperidines; Predictive Value of Tests; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Treatment Outcome | 2019 |
Patient-reported outcomes for tofacitinib with and without methotrexate, or adalimumab with methotrexate, in rheumatoid arthritis: a phase IIIB/IV trial.
Topics: Adalimumab; Arthritis, Rheumatoid; Drug Therapy, Combination; Humans; Methotrexate; Middle Aged; Piperidines; Pyrimidines; Pyrroles; Severity of Illness Index; Treatment Outcome | 2019 |
Efficacy and Safety of PF-06651600 (Ritlecitinib), a Novel JAK3/TEC Inhibitor, in Patients With Moderate-to-Severe Rheumatoid Arthritis and an Inadequate Response to Methotrexate.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Double-Blind Method; Female; Humans; Janus Kinase 3; Male; Middle Aged; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Treatment Outcome | 2020 |
Associations between Patient Global Assessment scores and pain, physical function, and fatigue in rheumatoid arthritis: a post hoc analysis of data from phase 3 trials of tofacitinib.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Fatigue; Humans; Pain; Piperidines; Pyrimidines; Pyrroles; Treatment Outcome | 2020 |
Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme.
Topics: Adult; Arthritis, Rheumatoid; Humans; Piperidines; Pyrimidines; Pyrroles; Treatment Outcome | 2020 |
Estimated medical expenditure and risk of job loss among rheumatoid arthritis patients undergoing tofacitinib treatment: post hoc analyses of two randomized clinical trials.
Topics: Adalimumab; Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Cost of Illness; Double-Blind Method; Drug Therapy, Combination; Female; Health Expenditures; Humans; Male; Methotrexate; Middle Aged; Piperidines; Pyrimidines; Pyrroles; Return to Work; Risk Factors; Treatment Outcome | 2017 |
Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial.
Topics: Adalimumab; Administration, Oral; Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Male; Methotrexate; Middle Aged; Piperidines; Pyrimidines; Pyrroles; Severity of Illness Index; Treatment Outcome | 2017 |
The Safety and Immunogenicity of Live Zoster Vaccination in Patients With Rheumatoid Arthritis Before Starting Tofacitinib: A Randomized Phase II Trial.
Topics: Aged; Antibodies, Viral; Antirheumatic Agents; Arthritis, Rheumatoid; Double-Blind Method; Drug Therapy, Combination; Enzyme-Linked Immunosorbent Assay; Enzyme-Linked Immunospot Assay; Female; Herpes Zoster; Herpes Zoster Vaccine; Herpesvirus 3, Human; Humans; Immunogenicity, Vaccine; Immunoglobulin G; Male; Methotrexate; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; T-Lymphocytes | 2017 |
Effect of Glucocorticoids on the Clinical and Radiographic Efficacy of Tofacitinib in Patients with Rheumatoid Arthritis: A Posthoc Analysis of Data from 6 Phase III Studies.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Disability Evaluation; Disease Progression; Double-Blind Method; Drug Synergism; Drug Therapy, Combination; Female; Follow-Up Studies; Glucocorticoids; Health Surveys; Humans; Male; Methotrexate; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Treatment Outcome | 2018 |
Tofacitinib Therapy for Rheumatoid Arthritis: A Direct Comparison Study between Biologic-naïve and Experienced Patients.
Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Biological Products; Drug Therapy, Combination; Female; Humans; Male; Methotrexate; Middle Aged; Piperidines; Pyrimidines; Pyrroles; Severity of Illness Index; Treatment Outcome | 2018 |
Tofacitinib with conventional synthetic disease-modifying antirheumatic drugs in Chinese patients with rheumatoid arthritis: Patient-reported outcomes from a Phase 3 randomized controlled trial.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; China; Disability Evaluation; Double-Blind Method; Drug Administration Schedule; Drug Substitution; Drug Therapy, Combination; Female; Health Status; Humans; Male; Middle Aged; Pain Measurement; Patient Reported Outcome Measures; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Quality of Life; Recovery of Function; Time Factors; Treatment Outcome; Young Adult | 2018 |
Reversibility of peripheral blood leukocyte phenotypic and functional changes after exposure to and withdrawal from tofacitinib, a Janus kinase inhibitor, in healthy volunteers.
Topics: Adult; Aged; Arthritis, Rheumatoid; Female; Healthy Volunteers; Humans; Janus Kinase Inhibitors; Leukocytes; Lymphocyte Count; Male; Middle Aged; Phenotype; Piperidines; Pyrimidines; Pyrroles; T-Lymphocytes | 2018 |
Evaluation of disease activity in patients with rheumatoid arthritis treated with tofacitinib by RAPID3: post hoc analyses from two phase 3 trials.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Female; Humans; Male; Methotrexate; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Remission Induction; Treatment Outcome | 2018 |
Tofacitinib in Rheumatoid Arthritis: Lack of Early Change in Disease Activity and the Probability of Achieving Low Disease Activity at Month 6.
Topics: Adult; Aged; Arthritis, Rheumatoid; Disease Progression; Double-Blind Method; Female; Humans; Male; Middle Aged; Piperidines; Probability; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Time Factors; Treatment Outcome | 2019 |
Analysis of miRNA expression in patients with rheumatoid arthritis during remission and relapse after a 5-year trial of tofacitinib treatment.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Female; Humans; Male; MicroRNAs; Middle Aged; Piperidines; Pyrimidines; Pyrroles; Recurrence | 2018 |
Tofacitinib, an oral Janus kinase inhibitor, in patients from Brazil with rheumatoid arthritis: Pooled efficacy and safety analyses.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Blood Sedimentation; Brazil; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Janus Kinase Inhibitors; Male; Methotrexate; Middle Aged; Patient Reported Outcome Measures; Piperidines; Pyrimidines; Pyrroles; Treatment Outcome | 2018 |
Modified- versus immediate-release tofacitinib in Japanese rheumatoid arthritis patients: a randomized, phase III, non-inferiority study.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Delayed-Action Preparations; Double-Blind Method; Female; Humans; Janus Kinase Inhibitors; Japan; Male; Middle Aged; Piperidines; Pyrimidines; Pyrroles; Treatment Outcome | 2019 |
A pooled analysis of the safety of tofacitinib as monotherapy or in combination with background conventional synthetic disease-modifying antirheumatic drugs in a Phase 3 rheumatoid arthritis population.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Arthritis, Rheumatoid; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Methotrexate; Middle Aged; Piperidines; Pyrimidines; Pyrroles; Treatment Outcome; Young Adult | 2018 |
Efficacy and Safety of Tofacitinib in Chinese Patients with Rheumatoid Arthritis.
Topics: Administration, Oral; Adult; Aged; Arthritis, Rheumatoid; Asian People; Female; Humans; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Surveys and Questionnaires; Young Adult | 2018 |
Tofacitinib in Combination With Methotrexate in Patients With Rheumatoid Arthritis: Clinical Efficacy, Radiographic, and Safety Outcomes From a Twenty-Four-Month, Phase III Study.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Female; Humans; Janus Kinase Inhibitors; Male; Methotrexate; Middle Aged; Piperidines; Pyrimidines; Pyrroles; Treatment Outcome | 2019 |
Treatment outcomes in patients with seropositive versus seronegative rheumatoid arthritis in Phase III randomised clinical trials of tofacitinib.
Topics: Adult; Aged; Aged, 80 and over; Anti-Citrullinated Protein Antibodies; Arthritis, Rheumatoid; Biomarkers; Female; Humans; Janus Kinase Inhibitors; Male; Middle Aged; Patient Reported Outcome Measures; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Rheumatoid Factor; Risk Factors; Treatment Outcome; Young Adult | 2019 |
Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study.
Topics: Administration, Oral; Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Cardiovascular Diseases; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Herpes Zoster; Humans; Male; Middle Aged; Neoplasms; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Time Factors; Treatment Outcome | 2019 |
Live Zoster Vaccine in Patients With Rheumatoid Arthritis Treated With Tofacitinib With or Without Methotrexate, or Adalimumab With Methotrexate: A Post Hoc Analysis of Data From a Phase IIIb/IV Randomized Study.
Topics: Adalimumab; Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Female; Herpes Zoster; Herpes Zoster Vaccine; Humans; Incidence; Janus Kinase Inhibitors; Male; Methotrexate; Middle Aged; Piperidines; Pyrimidines; Pyrroles | 2020 |
Open-label tofacitinib and double-blind atorvastatin in rheumatoid arthritis patients: a randomised study.
Topics: Administration, Oral; Adult; Arthritis, Rheumatoid; Atorvastatin; Cardiovascular Diseases; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Middle Aged; Piperidines; Placebos; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Treatment Outcome | 2014 |
Tofacitinib prevents radiographic progression in rheumatoid arthritis.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Cohort Studies; Disease Progression; Female; Humans; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Radiography; Severity of Illness Index; Treatment Outcome | 2013 |
Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Janus Kinase 3; Male; Methotrexate; Middle Aged; Piperidines; Pyrimidines; Pyrroles; Remission Induction; Treatment Outcome | 2013 |
Effects of tofacitinib on lymphocytes in rheumatoid arthritis: relation to efficacy and infectious adverse events.
Topics: Adult; Aged; Arthritis, Rheumatoid; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cell Count; Cell Proliferation; Double-Blind Method; Female; Humans; In Vitro Techniques; Infections; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Risk Factors; Severity of Illness Index; Treatment Outcome | 2014 |
Effects of Janus kinase inhibitor tofacitinib on circulating serum amyloid A and interleukin-6 during treatment for rheumatoid arthritis.
Topics: Adult; Anti-Inflammatory Agents; Antimetabolites, Antineoplastic; Arthritis, Rheumatoid; C-Reactive Protein; Double-Blind Method; Down-Regulation; Female; Humans; Interleukin-6; Janus Kinase 3; Male; Methotrexate; Middle Aged; Piperidines; Placebos; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Receptors, Interleukin-6; Serum Amyloid A Protein | 2014 |
Tofacitinib versus methotrexate in rheumatoid arthritis.
Topics: Administration, Oral; Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Cholesterol; Creatinine; Dose-Response Relationship, Drug; Double-Blind Method; Female; Herpes Zoster; Humans; Janus Kinase 3; Male; Methotrexate; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles | 2014 |
Changes in serum creatinine in patients with active rheumatoid arthritis treated with tofacitinib: results from clinical trials.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; C-Reactive Protein; Creatinine; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Inflammation; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles | 2014 |
Tofacitinib with methotrexate in third-line treatment of patients with active rheumatoid arthritis: patient-reported outcomes from a phase III trial.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Methotrexate; Middle Aged; Piperidines; Pyrimidines; Pyrroles; Self Report; Treatment Outcome | 2015 |
The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Chemokines; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Janus Kinase 1; Male; Matrix Metalloproteinase 1; Matrix Metalloproteinase 3; Methotrexate; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; RNA, Messenger; Signal Transduction; STAT Transcription Factors; Synovial Membrane; Treatment Outcome | 2015 |
Potential mechanisms leading to the abnormal lipid profile in patients with rheumatoid arthritis versus healthy volunteers and reversal by tofacitinib.
Topics: Adolescent; Adult; Aged; Arthritis, Rheumatoid; Biomarkers; Cholesterol; Female; Healthy Volunteers; Humans; Hungary; Lipoproteins; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Young Adult | 2015 |
Efficacy and safety of tofacitinib as monotherapy in Japanese patients with active rheumatoid arthritis: a 12-week, randomized, phase 2 study.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Double-Blind Method; Female; Follow-Up Studies; Humans; Janus Kinase 3; Japan; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Time Factors; Treatment Outcome | 2015 |
The effect of tofacitinib on pneumococcal and influenza vaccine responses in rheumatoid arthritis.
Topics: Adult; Aged; Aged, 80 and over; Arthritis, Rheumatoid; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Immunocompromised Host; Immunosuppressive Agents; Influenza Vaccines; Influenza, Human; Male; Methotrexate; Middle Aged; Piperidines; Pneumococcal Infections; Pneumococcal Vaccines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Young Adult | 2016 |
Evaluation of the effect of tofacitinib on measured glomerular filtration rate in patients with active rheumatoid arthritis: results from a randomised controlled trial.
Topics: Adult; Aged; Arthritis, Rheumatoid; Creatinine; Female; Glomerular Filtration Rate; Humans; Kidney; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Young Adult | 2015 |
Efficacy and safety of tofacitinib following inadequate response to conventional synthetic or biological disease-modifying antirheumatic drugs.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Male; Methotrexate; Middle Aged; Piperidines; Pyrimidines; Pyrroles; Treatment Outcome | 2016 |
Effects of tofacitinib monotherapy on patient-reported outcomes in a randomized phase 3 study of patients with active rheumatoid arthritis and inadequate responses to DMARDs.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Middle Aged; Piperidines; Pyrimidines; Pyrroles; Quality of Life; Self Report; Surveys and Questionnaires; Treatment Outcome | 2015 |
Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study.
Topics: Administration, Oral; Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Janus Kinase 3; Japan; Male; Methotrexate; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Time Factors; Treatment Outcome | 2016 |
Tofacitinib or adalimumab versus placebo: patient-reported outcomes from a phase 3 study of active rheumatoid arthritis.
Topics: Adalimumab; Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Double-Blind Method; Female; Humans; Male; Methotrexate; Middle Aged; Patient Reported Outcome Measures; Piperidines; Pyrimidines; Pyrroles; Quality of Life; Severity of Illness Index; Treatment Outcome | 2016 |
Comparing the effects of tofacitinib, methotrexate and the combination, on bone marrow oedema, synovitis and bone erosion in methotrexate-naive, early active rheumatoid arthritis: results of an exploratory randomised MRI study incorporating semiquantitati
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Bone Density; Bone Marrow; Bone Marrow Diseases; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Edema; Female; Hand; Humans; Magnetic Resonance Imaging; Male; Methotrexate; Middle Aged; Piperidines; Pyrimidines; Pyrroles; Synovitis; Treatment Outcome; Wrist Joint | 2016 |
Switching from adalimumab to tofacitinib in the treatment of patients with rheumatoid arthritis.
Topics: Adalimumab; Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Double-Blind Method; Drug Substitution; Female; Humans; Male; Middle Aged; Piperidines; Pyrimidines; Pyrroles; Treatment Outcome | 2016 |
Tofacitinib in Combination With Conventional Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis: Patient-Reported Outcomes From a Phase III Randomized Controlled Trial.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Patient Reported Outcome Measures; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Recovery of Function; Remission Induction; Time Factors; Treatment Outcome | 2017 |
Efficacy of tofacitinib in patients with rheumatoid arthritis stratified by background methotrexate dose group.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Blood Sedimentation; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Janus Kinases; Male; Methotrexate; Middle Aged; Piperidines; Pyrimidines; Pyrroles; Regression Analysis; Surveys and Questionnaires; Treatment Outcome | 2017 |
[Comparative assessment of antiinflammatory action of atorvastatin in ischemic heart disease and rheumatoid arthritis].
Topics: Arthritis, Rheumatoid; Atorvastatin; C-Reactive Protein; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Ischemia; Prospective Studies; Pyrroles; Treatment Outcome | 2008 |
The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo.
Topics: Arthritis, Rheumatoid; Cholesterol, HDL; Cholesterol, LDL; Creatinine; Dose-Response Relationship, Drug; Double-Blind Method; Female; Headache; Humans; International Cooperation; Janus Kinases; Male; Middle Aged; Nausea; Piperidines; Pyrimidines; Pyrroles; Treatment Outcome | 2009 |
Improved pain, physical functioning and health status in patients with rheumatoid arthritis treated with CP-690,550, an orally active Janus kinase (JAK) inhibitor: results from a randomised, double-blind, placebo-controlled trial.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Dose-Response Relationship, Drug; Epidemiologic Methods; Female; Humans; Janus Kinase 3; Male; Middle Aged; Pain; Pain Measurement; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Recovery of Function; Treatment Outcome | 2010 |
[The use of atorvastatin in patients with rheumatoid arthritis with hyperlipidemia].
Topics: Administration, Oral; Adult; Aged; Arthritis, Rheumatoid; Atorvastatin; C-Reactive Protein; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipids; Male; Middle Aged; Pyrroles; Treatment Outcome; Vascular Resistance | 2009 |
A semi-mechanistic model of CP-690,550-induced reduction in neutrophil counts in patients with rheumatoid arthritis.
Topics: Adolescent; Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Models, Biological; Neutropenia; Piperidines; Pyrimidines; Pyrroles; Time Factors | 2010 |
Co-administration of the JAK inhibitor CP-690,550 and methotrexate is well tolerated in patients with rheumatoid arthritis without need for dose adjustment.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Dose-Response Relationship, Drug; Drug Interactions; Drug Therapy, Combination; Female; Humans; Janus Kinase 3; Male; Methotrexate; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Treatment Outcome | 2010 |
Effect of atorvastatin on inflammation and modification of vascular risk factors in rheumatoid arthritis.
Topics: Adiponectin; Adult; Aged; Analysis of Variance; Antirheumatic Agents; Arthritis, Rheumatoid; Atorvastatin; Drug Therapy, Combination; Endothelium, Vascular; Female; Forearm; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Lipids; Male; Methotrexate; Middle Aged; Prednisone; Pyrroles; Regional Blood Flow; Resistin; Risk Factors; Severity of Illness Index; Tumor Necrosis Factor-alpha | 2011 |
Atorvastatin upregulates regulatory T cells and reduces clinical disease activity in patients with rheumatoid arthritis.
Topics: Adult; Anticholesteremic Agents; Arthritis, Rheumatoid; Atorvastatin; Female; Heptanoic Acids; Humans; Male; Middle Aged; Pyrroles; Signal Transduction; T-Lymphocytes, Regulatory | 2011 |
Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs.
Topics: Adalimumab; Administration, Oral; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Dose-Response Relationship, Drug; Double-Blind Method; Drug Substitution; Drug Tolerance; Female; Health Status; Humans; Injections, Subcutaneous; Janus Kinase 3; Joints; Male; Methotrexate; Middle Aged; Pilot Projects; Piperidines; Pyrimidines; Pyrroles; Recovery of Function | 2012 |
A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Methotrexate; Middle Aged; Piperidines; Pyrimidines; Pyrroles; Treatment Outcome | 2012 |
In vitro and in vivo analysis of a JAK inhibitor in rheumatoid arthritis.
Topics: Animals; Antirheumatic Agents; Arthritis, Experimental; Arthritis, Rheumatoid; CD4-Positive T-Lymphocytes; Cells, Cultured; Cytokines; Dose-Response Relationship, Drug; Double-Blind Method; Humans; Isoenzymes; Janus Kinase 3; Mice; Mice, SCID; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Signal Transduction | 2012 |
Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis.
Topics: Activities of Daily Living; Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Disability Evaluation; Double-Blind Method; Enzyme Inhibitors; Female; Humans; Janus Kinase 3; Least-Squares Analysis; Leukocyte Count; Male; Middle Aged; Neutrophils; Piperidines; Pyrimidines; Pyrroles; Severity of Illness Index; Treatment Outcome | 2012 |
Tofacitinib or adalimumab versus placebo in rheumatoid arthritis.
Topics: Adalimumab; Adult; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Cholesterol; Double-Blind Method; Drug Therapy, Combination; Enzyme Inhibitors; Female; Humans; Janus Kinase 3; Least-Squares Analysis; Leukocyte Count; Lipoproteins; Male; Methotrexate; Middle Aged; Neutrophils; Piperidines; Pyrimidines; Pyrroles; Treatment Outcome | 2012 |
Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial.
Topics: Adult; Aged; Arthritis, Rheumatoid; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Janus Kinases; Male; Maximum Tolerated Dose; Methotrexate; Middle Aged; Pain Measurement; Piperidines; Pyrimidines; Pyrroles; Recurrence; Risk Assessment; Severity of Illness Index; Time Factors; Treatment Failure; Treatment Outcome; Tumor Necrosis Factor-alpha | 2013 |
Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Drug Resistance; Female; Humans; Janus Kinase 3; Male; Methotrexate; Middle Aged; Motor Activity; Piperidines; Pyrimidines; Pyrroles; Radiography; Treatment Outcome | 2013 |
Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial.
Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Atorvastatin; Biomarkers; Blood Sedimentation; Blood Viscosity; C-Reactive Protein; Cardiovascular Diseases; Double-Blind Method; Drug Therapy, Combination; Female; Glucocorticoids; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Methotrexate; Middle Aged; Pyrroles; Risk Factors; von Willebrand Factor | 2004 |
Effects of high-dose atorvastatin on antiinflammatory properties of high density lipoprotein in patients with rheumatoid arthritis: a pilot study.
Topics: Anti-Inflammatory Agents; Anticholesteremic Agents; Arthritis, Rheumatoid; Atorvastatin; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Humans; Lipoproteins, HDL; Male; Middle Aged; Pilot Projects; Pyrroles | 2007 |
Long-term efficacy and safety of tolmetin sodium in treatment of geriatric patients with rheumatoid arthritis and osteoarthritis: a retrospective study.
Topics: Aged; Arthritis, Rheumatoid; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Male; Osteoarthritis; Pyrroles; Retrospective Studies; Time Factors; Tolmetin | 1983 |
[Treatment of gonarthrosis with tolectin].
Topics: Adult; Aged; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Clinical Trials as Topic; Female; Humans; Knee Joint; Male; Middle Aged; Pyrroles; Tolmetin | 1984 |
Effectiveness of tolmetin in rheumatoid arthritis: evaluation by means of a new method.
Topics: Adult; Arthritis, Rheumatoid; Clinical Trials as Topic; Female; Humans; Male; Middle Aged; Pyrroles; Tolmetin | 1982 |
Clinical experience with tolmetin sodium.
Topics: Arthritis, Rheumatoid; Aspirin; Clinical Trials as Topic; Double-Blind Method; Drug Tolerance; Fibromyalgia; Humans; Osteoarthritis; Phenylbutazone; Pyrroles; Tolmetin | 1980 |
Tolmetin sodium, a new anti-arthritis drug: double-blind and long-term studies.
Topics: Adult; Aged; Arthritis, Rheumatoid; Blood Pressure; Clinical Trials as Topic; Drug Evaluation; Female; Humans; Locomotion; Male; Middle Aged; Palliative Care; Placebos; Pyrroles; Time Factors; Tolmetin | 1976 |
[Drug evaluation of McN-2559 in chronic rheumatoid arthritis].
Topics: Adult; Aged; Arthritis, Rheumatoid; Clinical Trials as Topic; Drug Evaluation; Female; Humans; Male; Middle Aged; Pyrroles; Tolmetin | 1977 |
[Evaluation of the therapeutic activity of a new nonsteroid antiphlogistic drug, Tolectin in rheumatoid arthritis].
Topics: Arthritis, Rheumatoid; Clinical Trials as Topic; Drug Evaluation; Humans; Indomethacin; Pyrroles; Tolmetin | 1977 |
Clinical trial of tolmetin and aspirin in the treatment of rheumatoid arthritis.
Topics: Adult; Aged; Arthritis, Rheumatoid; Aspirin; Clinical Trials as Topic; Female; Humans; Male; Middle Aged; Pyrroles; Tolmetin | 1977 |
Clinical studies with tolmetin: open study and a double-blind cross-over comparison with aspirin in rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Aspirin; Clinical Trials as Topic; Female; Humans; Male; Middle Aged; Pyrroles; Tolmetin | 1978 |
Comparative efficacy of pirprofen and aspirin in rheumatoid arthritis.
Topics: Adult; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Aspirin; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Male; Phenylpropionates; Pyrroles | 1979 |
Pirprofen and aspirin in the treatment of rheumatoid arthritis.
Topics: Adult; Aged; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Aspirin; Clinical Trials as Topic; Double-Blind Method; Eye Diseases; Female; Gastrointestinal Diseases; Hearing Disorders; Humans; Male; Middle Aged; Phenylpropionates; Pyrroles | 1979 |
[1st data related to the study of a new drug. Tolmetin, in the treatment of rheumatoid arthritis. Preliminary communication].
Topics: Adult; Aged; Arthritis, Rheumatoid; Clinical Trials as Topic; Drug Evaluation; Female; Humans; Male; Middle Aged; Pyrroles; Tolmetin | 1975 |
Evaluation of tolmetin in the treatment of arthritis: open and controlled double-blind studies.
Topics: Adult; Arthritis, Rheumatoid; Chronic Disease; Clinical Trials as Topic; Drug Evaluation; Female; Humans; Indomethacin; Male; Middle Aged; Pyrroles; Tolmetin | 1976 |
A double-blind cross-over study of clopirac and ketoprofen in rheumatoid arthritis.
Topics: Anti-Inflammatory Agents; Arthritis, Rheumatoid; Benzophenones; Clinical Trials as Topic; Humans; Ketoprofen; Pyrroles | 1975 |
[Clinical study with 1-parachlorophenyl-2,5-dimethyl-3-pyrrolacetic acid "clopirac" (author's transl)].
Topics: Anti-Inflammatory Agents; Arthritis, Rheumatoid; Clinical Trials as Topic; Humans; Indomethacin; Pyrroles | 1975 |
A double-blind comparison of clopirac and indomethacin in the treatment of rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Clinical Trials as Topic; Humans; Indomethacin; Pyrroles | 1975 |
[Double-blind study of clopirac and indomethacin in rheumatoid arthritis (author's transl)].
Topics: Adult; Aged; Arthritis, Rheumatoid; Clinical Trials as Topic; Female; Humans; Indomethacin; Male; Middle Aged; Pyrroles | 1975 |
Treatment of rheumatoid arthritis with clopirac: comparison with aspirin.
Topics: Arthritis, Rheumatoid; Aspirin; Clinical Trials as Topic; Humans; Pyrroles | 1975 |
Double-blind study comparing clopirac with a placebo in rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Clinical Trials as Topic; Humans; Placebos; Pyrroles | 1975 |
[Study of a new anti-inflammatory agent in rheumatoid arthritis (author's transl)].
Topics: Anti-Inflammatory Agents; Arthritis, Rheumatoid; Clinical Trials as Topic; Humans; Indomethacin; Pyrroles | 1975 |
[Double-blind cross-over clinical study comparing clopirac with indomethacin in rheumatoid arthritis (author's transl)].
Topics: Arthritis, Rheumatoid; Clinical Trials as Topic; Humans; Indomethacin; Pyrroles | 1975 |
European experiences with tolmetin in the treatment of rheumatic diseases.
Topics: Aged; Arthritis, Rheumatoid; Clinical Trials as Topic; Female; Humans; Indomethacin; Male; Middle Aged; Osteoarthritis; Oxyphenbutazone; Placebos; Pyrroles; Rheumatic Diseases; Tolmetin; Wounds and Injuries | 1976 |
Tolmetin: an evaluation of a new preparation in the treatment of rheumatoid arthritis.
Topics: Adult; Aged; Arthritis, Rheumatoid; Aspirin; Clinical Trials as Topic; Drug Evaluation; Female; Humans; Male; Middle Aged; Pyrroles; Tolmetin | 1975 |
[Double blind and dosage studies on tolectine in rheumatoid arthritis].
Topics: Adult; Aged; Arthritis, Rheumatoid; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Evaluation; Female; Humans; Male; Middle Aged; Placebos; Pyrroles; Tolmetin | 1975 |
A dual approach to the evaluation of the efficacy of a new rheumatoid arthritic agent--pirprofen.
Topics: Adult; Aged; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Blood Pressure; Clinical Trials as Topic; Female; Heart Rate; Humans; Male; Middle Aged; Phenylpropionates; Placebos; Pyrroles | 1976 |
Double-blind cross-over study of clopirac and naproxen in rheumatoid arthritis.
Topics: Anti-Inflammatory Agents; Arthritis, Rheumatoid; Humans; Naphthaleneacetic Acids; Naproxen; Pyrroles | 1975 |
[Study in double-blind comparing clopirac to indomethacine in rheumatoid arthritis (author's transl)].
Topics: Arthritis, Rheumatoid; Humans; Indomethacin; Pyrroles | 1975 |
A clinical and biochemical assessment of prinomide in patients with rheumatoid arthritis.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Clinical Trials as Topic; Female; Humans; Male; Middle Aged; Pyrroles; Statistics as Topic | 1989 |
Tolmetin versus placebo for the treatment of rheumatoid arthritis: a sequential double-blind clinical trial.
Topics: Anti-Inflammatory Agents; Arthritis, Rheumatoid; Benzoates; Clinical Trials as Topic; Drug Evaluation; Female; Humans; Male; Placebos; Pyrroles | 1974 |
Tolerance to pirprofen and preliminary efficacy trial in rheumatoid arthritis.
Topics: Adult; Aged; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Clinical Trials as Topic; Drug Evaluation; Female; Humans; Indomethacin; Joints; Male; Middle Aged; Phenylpropionates; Placebos; Prisoners; Pyrroles; Time Factors | 1974 |
Tolectin for rheumatoid arthritis.
Topics: Anti-Inflammatory Agents; Arthritis, Rheumatoid; Benzoates; Clinical Trials as Topic; Humans; Phenylbutazone; Placebos; Pyrroles | 1974 |
218 other study(ies) available for pyrroles and Rheumatoid Arthritis
| Article | Year |
|---|---|
Systemic inflammatory responses after orthopedic surgery in patients with rheumatoid arthritis treated with tofacitinib.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Infant, Newborn; Orthopedic Procedures; Piperidines; Pyrimidines; Pyrroles; Retrospective Studies; Treatment Outcome | 2021 |
Tofacitinib for the treatment of rheumatoid arthritis: a real-world study in China.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; China; Humans; Piperidines; Pyrimidines; Pyrroles; Retrospective Studies; Treatment Outcome | 2022 |
Economic Benefit from Improvements in Quality of Life with Upadacitinib: Comparisons with Tofacitinib and Methotrexate in Patients with Rheumatoid Arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Clinical Trials, Phase III as Topic; Drug Therapy, Combination; Heterocyclic Compounds, 3-Ring; Humans; Methotrexate; Piperidines; Pyrimidines; Pyrroles; Quality of Life; Randomized Controlled Trials as Topic; Treatment Outcome | 2021 |
Quantification of the janus kinase 1 inhibitor upadacitinib in human plasma by LC-MS/MS.
Topics: Aminopyridines; Antirheumatic Agents; Arthritis, Rheumatoid; Chromatography, Liquid; Drug Monitoring; Heterocyclic Compounds, 3-Ring; Humans; Janus Kinase Inhibitors; Limit of Detection; Linear Models; Pyrroles; Reproducibility of Results; Tandem Mass Spectrometry | 2022 |
Effectiveness of baricitinib and tofacitinib compared with bDMARDs in RA: results from a cohort study using nationwide Swedish register data.
Topics: Abatacept; Antirheumatic Agents; Arthritis, Rheumatoid; Azetidines; Biological Products; Cohort Studies; Humans; Interleukin-6; Piperidines; Purines; Pyrazoles; Pyrimidines; Pyrroles; Rituximab; Sulfonamides; Sweden; Treatment Outcome; Tumor Necrosis Factor Inhibitors | 2022 |
Work productivity in rheumatoid arthritis patients from two Latin American countries treated with tofacitinib or biological DMARDs.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Efficiency; Humans; Latin America; Piperidines; Pyrimidines; Pyrroles; Treatment Outcome; Work Performance | 2022 |
Tailoring Tofacitinib Oral Therapy in Rheumatoid Arthritis: The TuTOR App.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Mobile Applications; Piperidines; Pyrimidines; Pyrroles; Treatment Outcome | 2022 |
Real-world evidence of the effectiveness and safety of generic tofacitinib in rheumatoid arthritis patients: a retrospective, single-centre analysis from Western India.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; COVID-19; Female; Humans; India; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Retrospective Studies; Treatment Outcome | 2022 |
Effectiveness and Safety of Tofacitinib in Canadian Patients With Rheumatoid Arthritis: Primary Results From a Prospective Observational Study.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Canada; Humans; Prospective Studies; Pyrroles; Treatment Outcome | 2023 |
[What do the results of the ORAL surveillance study mean for the treatment of rheumatoid arthritis with tofacitinib?]
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Reproducibility of Results; Treatment Outcome | 2022 |
Tofacitinib as a possible treatment for arthritis in an APDS2 patient.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Treatment Outcome | 2023 |
Efficacy and drug retention of tofacitinib in rheumatoid arthritis: from the nationwide Korean College of Rheumatology Biologics registry.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Biological Products; Female; Humans; Janus Kinase Inhibitors; Male; Middle Aged; Pyrroles; Republic of Korea; Rheumatology; Treatment Outcome | 2023 |
Tofacitinib treatment modulates the levels of several inflammation-related plasma proteins in rheumatoid arthritis and baseline levels of soluble biomarkers associate with the treatment response.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Biomarkers; Blood Proteins; Chemokines; Humans; Inflammation; Interleukin-6; Protein Kinase Inhibitors; Pyrroles; Treatment Outcome | 2022 |
Real-world Effectiveness and Safety of JAK Inhibitors in Rheumatoid Arthritis: A Single-centre Study.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Bayes Theorem; Humans; Janus Kinase Inhibitors; Pyrroles; Retrospective Studies | 2022 |
Safety and effectiveness of tofacitinib in Korean adult patients with rheumatoid arthritis: A post-marketing surveillance study.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Product Surveillance, Postmarketing; Prospective Studies; Pyrroles; Republic of Korea; Treatment Outcome | 2023 |
Effectiveness and safety profile of tofacitinib and baricitinib in rheumatoid arthritis patients: results from a 24-month real-life prospective study in Southern-Italy.
Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Middle Aged; Prospective Studies; Pyrroles; Treatment Outcome | 2022 |
Impact of cardiovascular risk enrichment on incidence of major adverse cardiovascular events in the tofacitinib rheumatoid arthritis clinical programme.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Cardiovascular Diseases; Heart Disease Risk Factors; Humans; Incidence; Pyrroles; Risk Factors; Treatment Outcome | 2023 |
Letter: tofacitinib in the real world - do clinical trial data stand up?
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Piperidines; Pyrimidines; Pyrroles | 2023 |
Development of a sensitive biochemical assay for the detection of tofacitinib adherence.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Pyrroles; Tandem Mass Spectrometry | 2023 |
Comparisons of treatment satisfaction and health-related quality of life in patients with rheumatoid arthritis treated with tofacitinib and adalimumab.
Topics: Adalimumab; Antirheumatic Agents; Arthritis, Rheumatoid; Cross-Sectional Studies; Humans; Patient Satisfaction; Personal Satisfaction; Pyrroles; Quality of Life; Treatment Outcome | 2023 |
Joint-level responses to tofacitinib and methotrexate: a post hoc analysis of data from ORAL Start.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Humans; Methotrexate; Pyrroles; Treatment Outcome | 2023 |
Outcomes of dose reduction, withdrawal, and restart of tofacitinib in patients with rheumatoid arthritis: a prospective observational study.
Topics: Aged; Arthritis, Rheumatoid; Female; Humans; Male; Middle Aged; Piperidines; Prospective Studies; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Symptom Flare Up | 2019 |
Experience with tofacitinib in Canada: patient characteristics and treatment patterns in rheumatoid arthritis over 3 years.
Topics: Adult; Age Factors; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Canada; Databases, Factual; Female; Humans; Male; Middle Aged; Piperidines; Practice Patterns, Physicians'; Pyrimidines; Pyrroles; Treatment Outcome | 2020 |
Quantitative tracking of inflammatory activity at the peak and trough plasma levels of tofacitinib, a Janus kinase inhibitor, via in vivo
Topics: Animals; Antirheumatic Agents; Arthritis, Experimental; Arthritis, Rheumatoid; Drug Administration Schedule; Fluorodeoxyglucose F18; Janus Kinase Inhibitors; Joints; Male; Mice, Inbred DBA; Piperidines; Positron-Emission Tomography; Predictive Value of Tests; Pyrimidines; Pyrroles; Radiopharmaceuticals; Whole Body Imaging | 2019 |
Changes in Serum Cytokines May Predict Therapeutic Efficacy of Tofacitinib in Rheumatoid Arthritis.
Topics: Adult; Arthritis, Rheumatoid; Cytokines; Female; Humans; Interleukin-17; Interleukin-6; Interleukins; Male; Middle Aged; Piperidines; Pyrimidines; Pyrroles; Tumor Necrosis Factor-alpha | 2019 |
IgA Vasculitis Developed as an Adverse Effect of Tofacitinib Taken for Rheumatoid Arthritis.
Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Female; Humans; Immunoglobulin A; Piperidines; Pyrimidines; Pyrroles; Tumor Necrosis Factor-alpha; Vasculitis | 2020 |
Alterations of voluntary behavior in the course of disease progress and pharmacotherapy in mice with collagen-induced arthritis.
Topics: Animals; Antirheumatic Agents; Arthritis, Experimental; Arthritis, Rheumatoid; Disease Models, Animal; Disease Progression; Humans; Joints; Male; Mice, Inbred DBA; Motor Activity; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Synovitis; Temperature | 2019 |
Janus kinase inhibitors for the treatment of rheumatoid arthritis demonstrate similar profiles of in vitro cytokine receptor inhibition.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Azetidines; Cell Line; Cytokines; Enzyme Assays; Female; Healthy Volunteers; Heterocyclic Compounds, 3-Ring; Humans; Inhibitory Concentration 50; Janus Kinase 1; Janus Kinase Inhibitors; Male; Piperidines; Purines; Pyrazoles; Pyridines; Pyrimidines; Pyrroles; Receptors, Cytokine; Sulfonamides; Triazoles | 2019 |
Inferring disease severity in rheumatoid arthritis using predictive modeling in administrative claims databases.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Databases, Factual; Female; Humans; Insurance Claim Review; Male; Middle Aged; Models, Biological; Piperidines; Pyrimidines; Pyrroles; Severity of Illness Index | 2019 |
Methotrexate-Induced Pneumonitis in Rheumatoid Arthritis: Long-term Treatment With Tofacitinib Therapy.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Humans; Methotrexate; Piperidines; Pneumonia; Pyrimidines; Pyrroles; Treatment Outcome | 2021 |
Relative efficacy and safety of tofacitinib, baricitinib, upadacitinib, and filgotinib in comparison to adalimumab in patients with active rheumatoid arthritis.
Topics: Adalimumab; Antirheumatic Agents; Arthritis, Rheumatoid; Azetidines; Bayes Theorem; Drug Therapy, Combination; Heterocyclic Compounds, 3-Ring; Humans; Methotrexate; Piperidines; Purines; Pyrazoles; Pyridines; Pyrimidines; Pyrroles; Sulfonamides; Treatment Outcome; Triazoles | 2020 |
Long-term effectiveness of live herpes zoster vaccine in patients with rheumatoid arthritis subsequently treated with tofacitinib.
Topics: Aged; Arthritis, Rheumatoid; Combined Modality Therapy; Female; Follow-Up Studies; Herpes Zoster Vaccine; Humans; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Severity of Illness Index; Time Factors; Treatment Outcome; Vaccines, Live, Unattenuated | 2020 |
The use of Janus kinase inhibitors in the time of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Topics: Arthritis, Rheumatoid; Azetidines; Betacoronavirus; Colitis, Ulcerative; Coronavirus Infections; COVID-19; Cytokines; Dermatitis, Atopic; Heterocyclic Compounds, 3-Ring; Humans; Immunomodulation; Janus Kinases; Nitriles; Pandemics; Piperidines; Pneumonia, Viral; Primary Myelofibrosis; Purines; Pyrazoles; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; SARS-CoV-2; STAT Transcription Factors; Sulfonamides | 2020 |
Cost-effectiveness analysis of treatment sequences containing tofacitinib for the treatment of rheumatoid arthritis in Spain.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Cost-Benefit Analysis; Drug Therapy, Combination; Humans; Methotrexate; Piperidines; Pyrimidines; Pyrroles; Spain; Treatment Outcome | 2020 |
Tailoring Tofacitinib Oral Therapy in Rheumatoid Arthritis: The TuTORApp-A Usability Study.
Topics: Adolescent; Adult; Arthritis, Rheumatoid; Computer Security; Female; Humans; Medication Adherence; Mobile Applications; Piperidines; Pregnancy; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Young Adult | 2020 |
Tofacitinib-induced Ramsay- Hunt Syndrome in a Patient with Rheumatoid Arthritis.
Topics: Arthritis, Rheumatoid; Female; Herpes Zoster Oticus; Humans; Middle Aged; Piperidines; Pyrimidines; Pyrroles | 2021 |
Incidence Rates of Interstitial Lung Disease Events in Tofacitinib-Treated Rheumatoid Arthritis Patients: Post Hoc Analysis From 21 Clinical Trials.
Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Incidence; Lung Diseases, Interstitial; Piperidines; Pyrimidines; Pyrroles; Treatment Outcome | 2021 |
Lipid Profiles in Patients With Ulcerative Colitis Receiving Tofacitinib-Implications for Cardiovascular Risk and Patient Management.
Topics: Arthritis, Rheumatoid; Cardiovascular Diseases; Cholesterol; Clinical Trials, Phase III as Topic; Colitis, Ulcerative; Heart Disease Risk Factors; Humans; Inflammation; Lipids; Lipoproteins, HDL; Lipoproteins, LDL; Piperidines; Protein Kinase Inhibitors; Psoriasis; Pyrimidines; Pyrroles; Risk Factors; Treatment Outcome | 2021 |
Lessons from tofacitinib in patients with cardiovascular risk factors: increased pulmonary embolism or isolated (thrombotic) pulmonary occlusion rates?
Topics: Arthritis, Psoriatic; Arthritis, Rheumatoid; Humans; Incidence; Piperidines; Psoriasis; Pulmonary Embolism; Pyrimidines; Pyrroles | 2020 |
Herpes Zoster in rheumatoid arthritis patients receiving tofacitinib, a single center experience from Taiwan.
Topics: Aged; Arthritis, Rheumatoid; Case-Control Studies; Female; Herpes Zoster; Humans; Incidence; Interferon-gamma; Lymphocyte Count; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; T-Lymphocytes; Taiwan | 2020 |
Real-World Evidence to Contextualize Clinical Trial Results and Inform Regulatory Decisions: Tofacitinib Modified-Release Once-Daily vs Immediate-Release Twice-Daily for Rheumatoid Arthritis.
Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Medicare; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Treatment Outcome; United States | 2021 |
Development of severe thrombocytopenia with TAFRO syndrome-like features in a patient with rheumatoid arthritis treated with a Janus kinase inhibitor: A case report.
Topics: Aged; Arthritis, Rheumatoid; Castleman Disease; Fatal Outcome; Female; Humans; Janus Kinase Inhibitors; Multiple Organ Failure; Piperidines; Pyrimidines; Pyrroles; Thrombocytopenia | 2020 |
Drug retention of sarilumab, baricitinib, and tofacitinib in patients with rheumatoid arthritis: the ANSWER cohort study.
Topics: Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Azetidines; Cohort Studies; Female; Humans; Methotrexate; Middle Aged; Pharmaceutical Preparations; Piperidines; Purines; Pyrazoles; Pyrimidines; Pyrroles; Retrospective Studies; Sulfonamides; Treatment Outcome | 2021 |
Effects of one-year tofacitinib therapy on bone metabolism in rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Bone Density; Humans; Piperidines; Pyrimidines; Pyrroles | 2021 |
Development and evaluation of tofacitinib transdermal system for the treatment of rheumatoid arthritis in rats.
Topics: Administration, Cutaneous; Animals; Arthritis, Rheumatoid; Drug Delivery Systems; Piperidines; Pyrimidines; Pyrroles; Rats; Transdermal Patch | 2021 |
Real-world comparative effectiveness and safety of tofacitinib and baricitinib in patients with rheumatoid arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Azetidines; Humans; Piperidines; Purines; Pyrazoles; Pyrimidines; Pyrroles; Sulfonamides; Treatment Outcome | 2021 |
Adherence to treatment with tofacitinib in patients with rheumatoid arthritis in daily clinical practice.
Topics: Adolescent; Antirheumatic Agents; Arthritis, Rheumatoid; Cross-Sectional Studies; Female; Humans; Male; Middle Aged; Piperidines; Pyrimidines; Pyrroles | 2022 |
Janus kinase inhibitors prevent migration of rheumatoid arthritis neutrophils towards interleukin-8, but do not inhibit priming of the respiratory burst or reactive oxygen species production.
Topics: Adult; Aged; Aged, 80 and over; Arthritis, Rheumatoid; Azetidines; Case-Control Studies; Cell Movement; Cells, Cultured; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Interleukin-8; Janus Kinases; Male; Middle Aged; Neutrophils; Piperidines; Protein Kinase Inhibitors; Purines; Pyrazoles; Pyrimidines; Pyrroles; Reactive Oxygen Species; Respiratory Burst; Sulfonamides; Tetradecanoylphorbol Acetate; United Kingdom | 2017 |
Cytomegalovirus retinitis followed by immune recovery uveitis in an elderly patient with rheumatoid arthritis undergoing administration of methotrexate and tofacitinib combination therapy.
Topics: Aged; Antiviral Agents; Arthritis, Rheumatoid; Cytomegalovirus Retinitis; Ganciclovir; Humans; Immunosuppressive Agents; Intravitreal Injections; Male; Methotrexate; Piperidines; Pyrimidines; Pyrroles; Uveitis | 2017 |
Discontinuation of tofacitinib after achieving low disease activity in patients with rheumatoid arthritis: a multicentre, observational study.
Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Disease Progression; Female; Humans; Male; Middle Aged; Piperidines; Prospective Studies; Pyrimidines; Pyrroles; Time Factors; Treatment Outcome; Withholding Treatment | 2017 |
Tofacitinib attenuates arthritis manifestations and reduces the pathogenic CD4 T cells in adjuvant arthritis rats.
Topics: Animals; Antirheumatic Agents; Arthritis, Experimental; Arthritis, Rheumatoid; C-Reactive Protein; CD4-Positive T-Lymphocytes; Foot; Foot Joints; Forelimb; Hindlimb; Interferon-gamma; Interleukin-1beta; Methotrexate; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Rats; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Spleen | 2017 |
Efficacy and safety at 24 weeks of daily clinical use of tofacitinib in patients with rheumatoid arthritis.
Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Female; Humans; Male; Middle Aged; Piperidines; Pyrimidines; Pyrroles | 2017 |
Jak3 deficiency blocks innate lymphoid cell development.
Topics: Animals; Arthritis, Rheumatoid; Bone Marrow Cells; Cell Differentiation; Cell Proliferation; Cells, Cultured; Humans; Immunity, Innate; Interferon-gamma; Janus Kinase 3; Killer Cells, Natural; Mice; Mice, Mutant Strains; Mutation; Phenotype; Piperidines; Pyrimidines; Pyrroles; Severe Combined Immunodeficiency | 2018 |
Electronically Activated Organoboron Catalysts for Enantioselective Propargyl Addition to Trifluoromethyl Ketones.
Topics: Arthritis, Rheumatoid; Benzamides; Boron Compounds; Catalysis; Electronics; Ketones; Molecular Structure; Morphinans; Pyridines; Pyrroles; Stereoisomerism | 2017 |
2017 American College of Rheumatology/American Association of Hip and Knee Surgeons Guideline for the Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty.
Topics: Antirheumatic Agents; Arthritis, Juvenile; Arthritis, Psoriatic; Arthritis, Rheumatoid; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Biological Products; Glucocorticoids; Humans; Immunosuppressive Agents; Lupus Erythematosus, Systemic; Orthopedics; Perioperative Care; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Rheumatic Diseases; Rheumatology; Societies, Medical; Spondylitis, Ankylosing; United States | 2017 |
Treating active rheumatoid arthritis with Janus kinase inhibitors.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Janus Kinase Inhibitors; Janus Kinases; Piperidines; Protein Kinase Inhibitors; Pyrroles | 2017 |
Tofacitinib restores the inhibition of reverse cholesterol transport induced by inflammation: understanding the lipid paradox associated with rheumatoid arthritis.
Topics: Animals; Arthritis, Rheumatoid; Cholesterol; Diet, High-Fat; Dose-Response Relationship, Drug; Inflammation; Lipids; Macrophages; Male; Piperidines; Pyrimidines; Pyrroles; Rabbits; Structure-Activity Relationship | 2017 |
Reactivation of hepatitis B virus infection in patients with rheumatoid arthritis receiving tofacitinib: a real-world study.
Topics: Adult; Arthritis, Rheumatoid; Female; Hepatitis B virus; Hepatitis B, Chronic; Humans; Male; Middle Aged; Piperidines; Pyrimidines; Pyrroles; Retrospective Studies; Taiwan; Virus Activation | 2018 |
Rheumatoid arthritis: JAK-ing up inadequate RA therapy.
Topics: Adalimumab; Arthritis, Rheumatoid; Double-Blind Method; Humans; Methotrexate; Piperidines; Pyrimidines; Pyrroles | 2017 |
Kinase inhibitors of the IGF-1R as a potential therapeutic agent for rheumatoid arthritis.
Topics: Animals; Antirheumatic Agents; Arthritis, Rheumatoid; Cell Line; Cell Proliferation; Female; Humans; Insulin-Like Growth Factor I; Macrophage Colony-Stimulating Factor; Mice; Neovascularization, Pathologic; Osteoclasts; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; RANK Ligand; Receptor, IGF Type 1; Receptors, Somatomedin; Signal Transduction | 2017 |
A study on the risk of fungal infection with tofacitinib (CP-690550), a novel oral agent for rheumatoid arthritis.
Topics: Administration, Oral; Adult; Animals; Arthritis, Rheumatoid; Candida albicans; Candidiasis; Disease Susceptibility; Female; Humans; Mice, Inbred BALB C; Neutrophil Activation; Neutrophils; Phagocytosis; Piperidines; Pyrimidines; Pyrroles; Risk Factors | 2017 |
Novel drug delivery of dual acting prodrugs of hydroxychloroquine with aryl acetic acid NSAIDs: Design, kinetics and pharmacological study.
Topics: Acetic Acid; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Experimental; Arthritis, Rheumatoid; Carrageenan; Diclofenac; Drug Design; Female; Freund's Adjuvant; Hydroxychloroquine; Inflammation; Male; Mice; Prodrugs; Pyrroles; Rats; Rats, Wistar | 2017 |
Editorial: Herpes Zoster: Fear the Infection, Value the Solution.
Topics: Arthritis, Rheumatoid; Fear; Herpes Zoster; Humans; Piperidines; Pyrimidines; Pyrroles; Vaccination | 2017 |
Herpes Zoster and Tofacitinib: Clinical Outcomes and the Risk of Concomitant Therapy.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Chloroquine; Clinical Trials as Topic; Databases, Factual; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Glucocorticoids; Herpes Zoster; Humans; Incidence; Isoxazoles; Leflunomide; Male; Methotrexate; Middle Aged; Multivariate Analysis; Piperidines; Proportional Hazards Models; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Risk Factors | 2017 |
Rheumatoid arthritis: Reducing the risk of herpes zoster.
Topics: Arthritis, Rheumatoid; Herpes Zoster; Humans; Piperidines; Pyrimidines; Pyrroles; Vaccination | 2017 |
Lymphoma in the Tofacitinib Rheumatoid Arthritis Clinical Development Program.
Topics: Adult; Aged; Arthritis, Rheumatoid; Case-Control Studies; Female; Humans; Janus Kinase 3; Lymphoma; Male; Middle Aged; Piperidines; Pyrimidines; Pyrroles | 2018 |
Design and Synthesis of a Highly Selective JAK3 Inhibitor for the Treatment of Rheumatoid Arthritis.
Topics: Animals; Antirheumatic Agents; Arthritis, Experimental; Arthritis, Rheumatoid; Disease Progression; Female; Humans; Inhibitory Concentration 50; Janus Kinase 3; Male; Mass Spectrometry; Mice; Mice, Inbred BALB C; Molecular Docking Simulation; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Rats; Rats, Sprague-Dawley | 2017 |
Tofacitinib improves atherosclerosis despite up-regulating serum cholesterol in patients with active rheumatoid arthritis: a cohort study.
Topics: Adult; Aged; Arthritis, Rheumatoid; Atherosclerosis; Carotid Arteries; Carotid Intima-Media Thickness; Cholesterol; Cohort Studies; Drug Administration Schedule; Female; Humans; Intention to Treat Analysis; Male; Methotrexate; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Risk Factors; Single-Blind Method; Surveys and Questionnaires; Ultrasonography; Up-Regulation | 2017 |
Treatment Persistence and Healthcare Costs Among Patients with Rheumatoid Arthritis Changing Biologics in the USA.
Topics: Abatacept; Adalimumab; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Biological Products; Certolizumab Pegol; Databases, Factual; Etanercept; Female; Humans; Infliximab; Male; Middle Aged; Piperidines; Pyrimidines; Pyrroles; Retrospective Studies; Tumor Necrosis Factor-alpha | 2017 |
NICE issues positive recommendation for XELJANZ®▼(tofacitinib citrate) as a new treatment option for adults with severe rheumatoid arthritis.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Approval; Humans; Piperidines; Pyrimidines; Pyrroles; United Kingdom | 2017 |
Outcomes after rheumatoid arthritis patients complete their participation in a long-term observational study with tofacitinib combined with methotrexate: practical and ethical implications in vulnerable populations after tofacitinib discontinuation.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Disability Evaluation; Disease Progression; Drug Therapy, Combination; Ethics, Research; Female; Humans; Male; Methotrexate; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Recurrence; Remission Induction; Research Design; Research Subjects; Time Factors; Treatment Outcome; Vulnerable Populations | 2018 |
A Case Series on Patients on Tofacitinib in Combination With a Biologic.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Psoriatic; Arthritis, Rheumatoid; Drug Monitoring; Drug Therapy, Combination; Female; Humans; Immunologic Factors; Janus Kinase 3; Male; Middle Aged; Piperidines; Pyrimidines; Pyrroles; Severity of Illness Index; Treatment Outcome | 2018 |
Bone remodelling: locus minori or unappreciated potential of tofacitinib?
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Bone Remodeling; Double-Blind Method; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Treatment Outcome | 2018 |
Safety signal detection and evaluation in clinical development programs: A case study of tofacitinib.
Topics: Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Arthritis, Rheumatoid; Clinical Trials as Topic; Feasibility Studies; Female; Humans; Incidence; Janus Kinase Inhibitors; Japan; Male; Middle Aged; Pancreatic Neoplasms; Pharmacovigilance; Piperidines; Product Surveillance, Postmarketing; Pyrimidines; Pyrroles | 2018 |
Tofacitinib for Psoriatic Arthritis.
Topics: Antirheumatic Agents; Arthritis, Psoriatic; Arthritis, Rheumatoid; Humans; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Treatment Outcome | 2018 |
Herpes zoster as a cause of atypical chronic ulcerations associated with tofacitinib.
Topics: Arthritis, Rheumatoid; Chronic Disease; Female; Herpes Zoster; Humans; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Skin; Skin Ulcer | 2018 |
Effectiveness and safety of tofacitinib in rheumatoid arthritis: a cohort study.
Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Cohort Studies; Female; Humans; Infections; Male; Methotrexate; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Retrospective Studies; Treatment Outcome | 2018 |
Stattic inhibits RANKL-mediated osteoclastogenesis by suppressing activation of STAT3 and NF-κB pathways.
Topics: Animals; Arthritis, Rheumatoid; Bone Resorption; Cyclic S-Oxides; Gene Expression Regulation; Genes, fos; Humans; Janus Kinases; Macrophages; Mice; NF-kappa B; NFATC Transcription Factors; Osteogenesis; Piperidines; Pyrimidines; Pyrroles; RANK Ligand; RAW 264.7 Cells; Signal Transduction; STAT3 Transcription Factor | 2018 |
Elderly-Onset Varicella Pneumonia in a Patient With Rheumatoid Arthritis Treated With Tofacitinib.
Topics: Aged; Arthritis, Rheumatoid; Chickenpox; Female; Herpesvirus 3, Human; Humans; Piperidines; Pneumonia, Viral; Protein Kinase Inhibitors; Pyrimidines; Pyrroles | 2018 |
Factors associated with physicians' prescriptions for rheumatoid arthritis drugs not filled by patients.
Topics: Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Arthritis, Rheumatoid; Female; Humans; Logistic Models; Male; Methotrexate; Middle Aged; Patient Compliance; Physicians; Piperidines; Prescriptions; Pyrimidines; Pyrroles; Risk Factors | 2018 |
JAK/STAT Blockade Alters Synovial Bioenergetics, Mitochondrial Function, and Proinflammatory Mediators in Rheumatoid Arthritis.
Topics: Arthritis, Rheumatoid; Cells, Cultured; Energy Metabolism; Fibroblasts; Humans; Inflammation Mediators; Janus Kinases; Mitochondria; Oncostatin M; Phosphorylation; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Signal Transduction; STAT Transcription Factors; Synovial Membrane | 2018 |
Discriminating phenotypic signatures identified for tocilizumab, adalimumab, and tofacitinib monotherapy and their combinations with methotrexate.
Topics: Adalimumab; Antibodies, Monoclonal, Humanized; Arthritis, Rheumatoid; Drug Therapy, Combination; Humans; Inflammation; Methotrexate; Phenotype; Piperidines; Pyrimidines; Pyrroles; Receptors, Interleukin-6; Signal Transduction | 2018 |
An Economic Evaluation of Tofacitinib Treatment in Rheumatoid Arthritis After Methotrexate or After 1 or 2 TNF Inhibitors from a U.S. Payer Perspective.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Biological Products; Clinical Decision-Making; Cost Savings; Cost-Benefit Analysis; Decision Support Techniques; Decision Trees; Drug Costs; Drug Substitution; Humans; Methotrexate; Models, Economic; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Remission Induction; Time Factors; Treatment Outcome; Tumor Necrosis Factor-alpha; United States | 2018 |
Development of a Janus Kinase Inhibitor Prodrug for the Treatment of Rheumatoid Arthritis.
Topics: Acrylamides; Administration, Oral; Animals; Ankle Joint; Arthritis, Experimental; Arthritis, Rheumatoid; Cells, Cultured; Janus Kinase Inhibitors; Janus Kinases; Macrophages; Male; Mice, Inbred C57BL; Piperidines; Primary Cell Culture; Prodrugs; Pyrimidines; Pyrroles; Rats; Rats, Inbred Lew; Signal Transduction; STAT6 Transcription Factor; Tissue Distribution; Treatment Outcome; X-Ray Microtomography | 2018 |
Modelling the cost-effectiveness of tofacitinib for the treatment of rheumatoid arthritis in the United States.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Cost Savings; Cost-Benefit Analysis; Humans; Models, Economic; Piperidines; Pyrimidines; Pyrroles; Quality of Life; Treatment Outcome; United States | 2018 |
Tofacitinib and Risk of Peripheral Neuropathy? Experience of 2 Cases in Patients With Rheumatoid Arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Humans; Peripheral Nervous System Diseases; Piperidines; Pyrimidines; Pyrroles; Treatment Outcome | 2021 |
Comments on the article "Effectiveness and safety of tofacitinib in rheumatoid arthritis: a cohort study".
Topics: Arthritis, Rheumatoid; Cohort Studies; Humans; Piperidines; Pyrimidines; Pyrroles | 2018 |
Effect of Janus kinase inhibition by tofacitinib on body composition and glucose metabolism.
Topics: Adiposity; Adult; Aged; Animals; Antirheumatic Agents; Arthritis, Rheumatoid; Body Composition; Diet, High-Fat; Female; Glucose; Humans; Janus Kinase Inhibitors; Lipolysis; Mice; Mice, Inbred C57BL; Middle Aged; Piperidines; Pyrimidines; Pyrroles; Weight Gain | 2018 |
Risk for Herpes Zoster in Tofacitinib-Treated Rheumatoid Arthritis Patients With and Without Concomitant Methotrexate and Glucocorticoids.
Topics: Aged; Arthritis, Rheumatoid; Databases, Factual; Drug Therapy, Combination; Female; Follow-Up Studies; Glucocorticoids; Herpes Zoster; Humans; Incidence; Janus Kinase Inhibitors; Male; Medicare; Methotrexate; Middle Aged; Multivariate Analysis; Piperidines; Pyrimidines; Pyrroles; Risk Assessment; Time Factors; United States | 2019 |
An Immune Suppression-associated EBV-positive Anaplastic Large Cell Lymphoma With a BRAF V600E Mutation.
Topics: Aged; Arthritis, Rheumatoid; Epstein-Barr Virus Infections; Humans; Immunocompromised Host; Lymphoma, Large-Cell, Anaplastic; Male; Mutation; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Pyrimidines; Pyrroles | 2019 |
Dr. Charles-Schoeman and E. Bananis Reply.
Topics: Arthritis, Rheumatoid; Glucocorticoids; Humans; Piperidines; Pyrimidines; Pyrroles | 2018 |
Effects of Co-medication with Glucocorticoids in Biologics Trials.
Topics: Arthritis, Rheumatoid; Biological Products; Glucocorticoids; Humans; Piperidines; Pyrimidines; Pyrroles | 2018 |
Decrease in 14-3-3η protein levels is correlated with improvement in disease activity in patients with rheumatoid arthritis treated with Tofacitinib.
Topics: 14-3-3 Proteins; Adult; Arthritis, Rheumatoid; Biomarkers; Cohort Studies; Female; Humans; Male; Middle Aged; Piperidines; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Pyrroles | 2019 |
Evaluation of the Short-, Mid-, and Long-Term Effects of Tofacitinib on Lymphocytes in Patients With Rheumatoid Arthritis.
Topics: Arthritis, Rheumatoid; B-Lymphocytes; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Humans; Incidence; Infections; Janus Kinase Inhibitors; Killer Cells, Natural; Lymphocyte Count; Piperidines; Pyrimidines; Pyrroles; T-Lymphocyte Subsets; T-Lymphocytes; Time Factors | 2019 |
HDAC10 upregulation contributes to interleukin 1β-mediated inflammatory activation of synovium-derived mesenchymal stem cells in temporomandibular joint.
Topics: Arthritis, Rheumatoid; Cells, Cultured; Fibroblasts; Histone Deacetylases; Humans; Hydroxamic Acids; Interleukin-1beta; Interleukin-8; Mesenchymal Stem Cells; NF-kappa B; Osteoarthritis; Pyrroles; Signal Transduction; Synovial Membrane; Synoviocytes; Temporomandibular Joint; Transcriptional Activation; Up-Regulation | 2019 |
Comparative Risk of Venous Thromboembolism in Rheumatoid Arthritis Patients Receiving Tofacitinib Versus Those Receiving Tumor Necrosis Factor Inhibitors: An Observational Cohort Study.
Topics: Adult; Aged; Arthritis, Rheumatoid; Cohort Studies; Databases, Factual; Female; Humans; Incidence; Janus Kinase Inhibitors; Male; Middle Aged; Piperidines; Proportional Hazards Models; Pulmonary Embolism; Pyrimidines; Pyrroles; Tumor Necrosis Factor Inhibitors; Venous Thromboembolism; Venous Thrombosis | 2019 |
Comparisons of hepatitis C viral replication in patients with rheumatoid arthritis receiving tocilizumab, abatacept and tofacitinib therapy.
Topics: Abatacept; Aged; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Piperidines; Prospective Studies; Pyrimidines; Pyrroles; Virus Replication | 2019 |
2017 recommendations of the Brazilian Society of Rheumatology for the pharmacological treatment of rheumatoid arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Brazil; Decision Making; Drug Substitution; Drug Therapy, Combination; Glucocorticoids; Humans; Hydroxychloroquine; Leflunomide; Methotrexate; Piperidines; Pyrimidines; Pyrroles; Rheumatology; Societies, Medical; Sulfasalazine | 2018 |
Reversible eruption of neurofibromatosis associated with tofacitinib therapy for rheumatoid arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Female; Fibroma; Humans; Middle Aged; Neurofibromatosis 1; Piperidines; Pyrimidines; Pyrroles; Skin Neoplasms | 2019 |
Design, synthesis and evaluation of novel 7H-pyrrolo[2,3-d]pyrimidin-4-amine derivatives as potent, selective and reversible Bruton's tyrosine kinase (BTK) inhibitors for the treatment of rheumatoid arthritis.
Topics: Agammaglobulinaemia Tyrosine Kinase; Animals; Arthritis, Experimental; Arthritis, Rheumatoid; Collagen; Dose-Response Relationship, Drug; Drug Design; Humans; Male; Mice; Mice, Inbred DBA; Molecular Docking Simulation; Molecular Structure; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Structure-Activity Relationship | 2019 |
Efficacy and safety of tofacitinib for the treatment of rheumatoid arthritis in patients from the Asia-Pacific region: Post-hoc analyses of pooled clinical study data.
Topics: Adult; Arthritis, Rheumatoid; Asia; Clinical Trials as Topic; Evidence-Based Medicine; Female; Humans; Janus Kinase Inhibitors; Male; Middle Aged; Neoplasms; Opportunistic Infections; Piperidines; Pyrimidines; Pyrroles; Recovery of Function; Remission Induction; Risk Factors; Time Factors; Treatment Outcome | 2019 |
Targeting Activated Synovial Fibroblasts in Rheumatoid Arthritis by Peficitinib.
Topics: Adamantane; Arthritis, Rheumatoid; Azetidines; Cell Proliferation; Chemokine CCL2; Fibroblasts; Humans; Interleukin-6; Janus Kinase Inhibitors; Niacinamide; Piperidines; Purines; Pyrazoles; Pyrimidines; Pyrroles; Sulfonamides; Synovial Membrane | 2019 |
Economic Evaluation of Sarilumab in the Treatment of Adult Patients with Moderately-to-Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic Disease-Modifying Antirheumatic Drugs.
Topics: Adalimumab; Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Certolizumab Pegol; Cost-Benefit Analysis; Etanercept; Female; Humans; Male; Methotrexate; Middle Aged; Piperidines; Pyrimidines; Pyrroles; Young Adult | 2019 |
Dynamics of body mass index and visceral adiposity index in patients with rheumatoid arthritis treated with tofacitinib.
Topics: Adiposity; Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Body Mass Index; Female; Humans; Intra-Abdominal Fat; Male; Middle Aged; Obesity, Abdominal; Piperidines; Prospective Studies; Pyrimidines; Pyrroles; Waist Circumference | 2019 |
Tofacitinib modulates the VZV-specific CD4+ T cell immune response in vitro in lymphocytes of patients with rheumatoid arthritis.
Topics: Antigens, CD; Antigens, Differentiation, T-Lymphocyte; Arthritis, Rheumatoid; CD4-Positive T-Lymphocytes; Cell Differentiation; Cell Proliferation; Herpesvirus 3, Human; Humans; Immunity, Cellular; Interferon-gamma; Lectins, C-Type; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Receptors, CCR5; Receptors, CXCR3; Th1 Cells | 2019 |
Chronic Inguinal Lymphadenitis in a Patient With Rheumatoid Arthritis Being Treated With Tofacitinib: Remission With Antituberculous Therapy and Discontinuation of JAK Inhibition.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Lymphadenitis; Piperidines; Pyrimidines; Pyrroles | 2020 |
Budget impact of introducing tofacitinib to the public hospital formulary in Hong Kong, 2017-2021.
Topics: Arthritis, Rheumatoid; Biological Products; Health Care Costs; Hong Kong; Hospitals, Public; Humans; Linear Models; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles | 2019 |
Tofacitinib: raising awareness of mycoses.
Topics: Aged; Arthritis, Rheumatoid; Fingers; Humans; Male; Mycoses; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles | 2019 |
IRF1 is critical for the TNF-driven interferon response in rheumatoid fibroblast-like synoviocytes : JAKinibs suppress the interferon response in RA-FLSs.
Topics: Animals; Arthritis, Rheumatoid; Azetidines; Biomarkers; Female; Gene Expression; Humans; Inflammation; Interferon Regulatory Factor-1; Interferons; Janus Kinase Inhibitors; Mice; Mice, Inbred C57BL; Mice, Transgenic; Piperidines; Purines; Pyrazoles; Pyrimidines; Pyrroles; Signal Transduction; Sulfonamides; Synovial Membrane; Synoviocytes; Tumor Necrosis Factor-alpha | 2019 |
Modeling Combined Anti-Inflammatory Effects of Dexamethasone and Tofacitinib in Arthritic Rats.
Topics: Animals; Anti-Inflammatory Agents; Arthritis, Experimental; Arthritis, Rheumatoid; Dexamethasone; Disease Progression; Dose-Response Relationship, Drug; Drug Therapy, Combination; Edema; Male; Pilot Projects; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Rats; Rats, Inbred Lew | 2019 |
Comparison of baricitinib, upadacitinib, and tofacitinib mediated regulation of cytokine signaling in human leukocyte subpopulations.
Topics: Arthritis, Rheumatoid; Azetidines; Biomarkers; Cytokines; Flow Cytometry; Heterocyclic Compounds, 3-Ring; Humans; Janus Kinase Inhibitors; Leukocytes, Mononuclear; Piperidines; Protein Kinase Inhibitors; Purines; Pyrazoles; Pyrimidines; Pyrroles; Signal Transduction; Sulfonamides | 2019 |
Retrospective Claims Analysis Indirectly Comparing Medication Adherence and Persistence Between Intravenous Biologics and Oral Small-Molecule Therapies in Inflammatory Bowel Diseases.
Topics: Administration, Intravenous; Administration, Oral; Adult; Aged; Antibodies, Monoclonal, Humanized; Arthritis, Rheumatoid; Biological Products; Female; Humans; Inflammatory Bowel Diseases; Infliximab; Insurance Claim Review; Male; Medication Adherence; Medication Therapy Management; Middle Aged; Piperidines; Proportional Hazards Models; Pyrimidines; Pyrroles; Retrospective Studies; United States | 2019 |
Risk Factors for Major Adverse Cardiovascular Events in Phase III and Long-Term Extension Studies of Tofacitinib in Patients With Rheumatoid Arthritis.
Topics: Aged; Arthritis, Rheumatoid; Blood Sedimentation; Cardiovascular Diseases; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials, Phase III as Topic; Female; Humans; Incidence; Male; Middle Aged; Myocardial Infarction; Piperidines; Proportional Hazards Models; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Risk Factors; Stroke; Treatment Outcome | 2019 |
Update in rheumatology: evidence published in 2012.
Topics: Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antirheumatic Agents; Antiviral Agents; Arthritis; Arthritis, Gouty; Arthritis, Rheumatoid; Autoimmune Diseases; Bacterial Infections; Calcitonin; Colchicine; Cryoglobulinemia; Death, Sudden, Cardiac; Drug Resistance, Viral; Enzyme Inhibitors; Female; Gout; Gout Suppressants; Hand Joints; Hepatitis C, Chronic; Humans; Hyperuricemia; Immunologic Factors; Janus Kinase 3; Male; Myocardial Infarction; Neoplasms; Osteoarthritis; Osteoarthritis, Hip; Osteoarthritis, Knee; Practice Guidelines as Topic; Protein Precursors; Pyrimidines; Pyrroles; Registries; Tumor Necrosis Factor-alpha | 2013 |
Tofacitinib for rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Female; Humans; Janus Kinases; Male; Methotrexate; Pyrimidines; Pyrroles; Tumor Necrosis Factor-alpha | 2013 |
Tofacitinib for rheumatoid arthritis - Authors' reply.
Topics: Arthritis, Rheumatoid; Female; Humans; Janus Kinases; Male; Methotrexate; Pyrimidines; Pyrroles; Tumor Necrosis Factor-alpha | 2013 |
Inhibition of Janus kinase/signal transducer and activator of transcription (JAK/STAT) signalling pathway in rheumatoid synovial fibroblasts using small molecule compounds.
Topics: Arthritis, Rheumatoid; Fibroblasts; Humans; Janus Kinases; Oncostatin M; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Signal Transduction; STAT Transcription Factors; Synovial Fluid; Synovial Membrane | 2013 |
Summaries for patients: tofacitinib for the treatment of rheumatoid arthritis.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Female; Humans; Janus Kinase 3; Male; Methotrexate; Middle Aged; Piperidines; Pyrimidines; Pyrroles; Remission Induction; Treatment Outcome | 2013 |
[A new therapeutical option for chronic inflammation in rheumatology: janus kinases inhibitors (JAK)].
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Chronic Disease; Drug Approval; Humans; Inflammation; Janus Kinases; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Rheumatic Diseases; Switzerland | 2014 |
Recent trends in orthopedic surgery aiming to improve quality of life for those with rheumatoid arthritis: data from a large observational cohort.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Chromones; Cohort Studies; Databases, Factual; Female; Humans; Japan; Joints; Male; Orthopedic Procedures; Piperidines; Pyrimidines; Pyrroles; Quality of Life; Sulfonamides; Tacrolimus | 2014 |
Comments on the paper showing an exceptionally favorable response to tofacitinib among Japanese rheumatoid patients and an issue surrounding clinical trial led by pharmaceutical company.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Female; Humans; Male; Methotrexate; Pyrimidines; Pyrroles | 2015 |
Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis.
Topics: Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Databases, Factual; Female; Herpes Zoster; Humans; Male; Middle Aged; Piperidines; Pyrimidines; Pyrroles; Treatment Outcome; Young Adult | 2014 |
Rheumatoid arthritis: can tofacitinib be used as first-line monotherapy for RA?
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Female; Humans; Male; Methotrexate; Piperidines; Pyrimidines; Pyrroles | 2014 |
Could tofacitinib, the first oral small-molecule inhibitor proven for use in active rheumatoid arthritis (RA) patients with insufficient response to methotrexate, be the breakthrough drug for RA?
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Piperidines; Pyrimidines; Pyrroles | 2014 |
Tofacitinib versus methotrexate in rheumatoid arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Female; Humans; Male; Methotrexate; Piperidines; Pyrimidines; Pyrroles | 2014 |
Tofacitinib versus methotrexate in rheumatoid arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Female; Humans; Male; Methotrexate; Piperidines; Pyrimidines; Pyrroles | 2014 |
Tofacitinib versus methotrexate in rheumatoid arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Female; Humans; Male; Methotrexate; Piperidines; Pyrimidines; Pyrroles | 2014 |
Rheumatoid arthritis in 2014: Exciting times for RA research.
Topics: Animals; Arthritis, Rheumatoid; Disease Models, Animal; Humans; Inflammation; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; T-Lymphocytes, Regulatory | 2015 |
Response to Dr Minota's Letter to the Editor of Modern Rheumatology Regarding a Study of Tofacitinib in Japanese Patients with Rheumatoid Arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Female; Humans; Immunomodulation; Male; Methotrexate; Pyrimidines; Pyrroles | 2016 |
Super-enhancers delineate disease-associated regulatory nodes in T cells.
Topics: Animals; Arthritis, Rheumatoid; Basic-Leucine Zipper Transcription Factors; Cell Differentiation; Cell Lineage; Enhancer Elements, Genetic; Gene Expression Regulation; Genetic Predisposition to Disease; Janus Kinase 3; Mice; Mice, Inbred C57BL; p300-CBP Transcription Factors; Piperidines; Pyrimidines; Pyrroles; RNA, Untranslated; T-Lymphocytes, Helper-Inducer; Transcription, Genetic | 2015 |
Potent anti-inflammatory effects of the narrow spectrum kinase inhibitor RV1088 on rheumatoid arthritis synovial membrane cells.
Topics: Acetamides; Adalimumab; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Dasatinib; Dose-Response Relationship, Drug; Humans; Inflammation Mediators; Interleukin-6; Interleukin-8; Macrophages; Monocytes; Naphthalenes; Oxazines; Piperidines; Primary Cell Culture; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Pyrimidines; Pyrroles; RNA, Small Interfering; Signal Transduction; Synovial Membrane; Tumor Necrosis Factor-alpha; Urea | 2015 |
Cost-effectiveness of Tofacitinib in the Treatment of Moderate to Severe Rheumatoid Arthritis in South Korea.
Topics: Adult; Arthritis, Rheumatoid; Cost-Benefit Analysis; Female; Humans; Janus Kinase 3; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Quality of Life; Republic of Korea; Severity of Illness Index; Surveys and Questionnaires | 2015 |
Simultaneous inhibition of JAK and SYK kinases ameliorates chronic and destructive arthritis in mice.
Topics: Animals; Antirheumatic Agents; Arthritis, Experimental; Arthritis, Rheumatoid; Cyclohexylamines; Disease Models, Animal; Drug Therapy, Combination; Enzyme-Linked Immunosorbent Assay; Flow Cytometry; Immunophenotyping; Intracellular Signaling Peptides and Proteins; Janus Kinases; Male; Mice; Mice, Inbred BALB C; Mice, Inbred DBA; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Syk Kinase | 2015 |
Initial Experience With Tofacitinib in Clinical Practice: Treatment Patterns and Costs of Tofacitinib Administered as Monotherapy or in Combination With Conventional Synthetic DMARDs in 2 US Health Care Claims Databases.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Databases, Factual; Drug Costs; Female; Humans; Male; Medication Adherence; Middle Aged; Piperidines; Pyrimidines; Pyrroles; Retrospective Studies | 2016 |
Real-world comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritis.
Topics: Adult; Age Factors; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Biological Products; Female; Herpes Simplex; Herpes Zoster; Herpesviridae Infections; Humans; Incidence; Male; Middle Aged; Piperidines; Proportional Hazards Models; Pyrimidines; Pyrroles; Risk Factors; Sex Factors | 2016 |
Brief Report: Risk of Gastrointestinal Perforation Among Rheumatoid Arthritis Patients Receiving Tofacitinib, Tocilizumab, or Other Biologic Treatments.
Topics: Abatacept; Adult; Age Factors; Aged; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Biological Products; Databases, Factual; Diverticulitis; Esophageal Perforation; Female; Gastroesophageal Reflux; Glucocorticoids; Humans; Incidence; Intestinal Perforation; Male; Medicare; Middle Aged; Peptic Ulcer; Piperidines; Prednisone; Proportional Hazards Models; Pyrimidines; Pyrroles; Risk Factors; Rituximab; Tumor Necrosis Factor-alpha; United States | 2016 |
Pregnancy Outcomes in the Tofacitinib Safety Databases for Rheumatoid Arthritis and Psoriasis.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Databases, Factual; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Infant, Newborn; Methotrexate; Piperidines; Pregnancy; Pregnancy Outcome; Protein Kinase Inhibitors; Psoriasis; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Young Adult | 2016 |
Cardiovascular safety findings in patients with rheumatoid arthritis treated with tofacitinib, an oral Janus kinase inhibitor.
Topics: Arthritis, Rheumatoid; Blood Pressure; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials, Phase III as Topic; Heart Failure; Humans; Hyperlipidemias; Hypertension; Incidence; Janus Kinases; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Triglycerides | 2016 |
Use of a risk characterisation approach to contextualise the safety profile of new rheumatoid arthritis treatments: a case study using tofacitinib.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Neoplasms; Opportunistic Infections; Piperidines; Pyrimidines; Pyrroles; Risk Assessment | 2017 |
An Economic Evaluation of Tofacitinib Treatment in Rheumatoid Arthritis: Modeling the Cost of Treatment Strategies in the United States.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Cost-Benefit Analysis; Humans; Models, Economic; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Treatment Outcome; United States | 2016 |
Successful treatment of palmoplantar pustulosis with rheumatoid arthritis, with tofacitinib: Impact of this JAK inhibitor on T-cell differentiation.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Female; Humans; Janus Kinase Inhibitors; Middle Aged; Piperidines; Psoriasis; Pyrimidines; Pyrroles; Treatment Outcome | 2016 |
JAK inhibitors: A broadening approach in rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Biosimilar Pharmaceuticals; Humans; Janus Kinase 3; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles | 2016 |
Impact of tofacitinib treatment on human B-cells in vitro and in vivo.
Topics: Antibody Formation; Arthritis, Rheumatoid; B-Lymphocytes; Cells, Cultured; Cytidine Deaminase; Humans; Immunoglobulin Class Switching; Immunomodulation; Interleukin Receptor Common gamma Subunit; Lymphocyte Activation; Lymphocyte Count; Piperidines; Plasma Cells; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Signal Transduction | 2017 |
Evaluation of Real-World Experience with Tofacitinib Compared with Adalimumab, Etanercept, and Abatacept in RA Patients with 1 Previous Biologic DMARD: Data from a U.S. Administrative Claims Database.
Topics: Abatacept; Adalimumab; Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Cohort Studies; Databases, Factual; Etanercept; Female; Humans; Insurance Claim Review; Male; Middle Aged; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Retrospective Studies; United States | 2016 |
Brief Report: Remission Rates With Tofacitinib Treatment in Rheumatoid Arthritis: A Comparison of Various Remission Criteria.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Clinical Trials, Phase III as Topic; Humans; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Remission Induction | 2017 |
Analysis of haematological changes in tofacitinib-treated patients with rheumatoid arthritis across phase 3 and long-term extension studies.
Topics: Adult; Aged; Arthritis, Rheumatoid; Blood Sedimentation; C-Reactive Protein; Cell Count; Clinical Trials, Phase III as Topic; Fatigue; Female; Hemoglobins; Humans; Longitudinal Studies; Lymphocyte Count; Male; Middle Aged; Neutrophils; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Treatment Outcome | 2017 |
Rheumatoid arthritis: TAK-ing the road to suppress inflammation in synovial fibroblasts.
Topics: Arthritis, Rheumatoid; Clinical Trials, Phase II as Topic; Cytokines; Fibroblasts; Humans; Lactones; MAP Kinase Kinase Kinases; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Resorcinols; Synovial Membrane | 2017 |
Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Arthritis, Rheumatoid; Clinical Trials as Topic; Female; Herpes Zoster; Humans; Immunocompromised Host; Incidence; Infections; Male; Middle Aged; Neoplasms; Opportunistic Infections; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Time Factors; Tuberculosis; Young Adult | 2017 |
Safety of Tofacitinib in the Treatment of Rheumatoid Arthritis in Latin America Compared With the Rest of the World Population.
Topics: Adult; Aged; Arthritis, Rheumatoid; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Monitoring; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Incidence; Janus Kinase Inhibitors; Latin America; Long Term Adverse Effects; Male; Middle Aged; Patient Safety; Piperidines; Pyrimidines; Pyrroles; Treatment Outcome | 2017 |
Social media for arthritis-related comparative effectiveness and safety research and the impact of direct-to-consumer advertising.
Topics: Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Comparative Effectiveness Research; Direct-to-Consumer Advertising; Herpes Zoster; Humans; Intestinal Perforation; Natural Language Processing; Piperidines; Pyrimidines; Pyrroles; Social Media | 2017 |
Discovery and evaluation of 1H-pyrrolo[2,3-b]pyridine based selective and reversible small molecule BTK inhibitors for the treatment of rheumatoid arthritis.
Topics: Agammaglobulinaemia Tyrosine Kinase; Animals; Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Male; Mice, Inbred C57BL; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Structure-Activity Relationship | 2017 |
Cost-effectiveness of sequenced treatment of rheumatoid arthritis with targeted immune modulators.
Topics: Abatacept; Adalimumab; Age Factors; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Biological Products; Certolizumab Pegol; Cost-Benefit Analysis; Drug Therapy, Combination; Etanercept; Humans; Infliximab; Models, Economic; Piperidines; Pyrimidines; Pyrroles; Quality-Adjusted Life Years; Severity of Illness Index; Sex Factors; Time Factors; Tumor Necrosis Factor-alpha; United States | 2017 |
Hydroxychloroquine-induced hyperpigmentation: the staining pattern.
Topics: Aged; Antacids; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Aspirin; Atorvastatin; Calcium Carbonate; Cardiomyopathy, Restrictive; Citalopram; Connective Tissue Diseases; Diuretics; Female; Furosemide; Glucosamine; Heptanoic Acids; Humans; Hydroxychloroquine; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperpigmentation; Lupus Erythematosus, Systemic; Magnesium; Metolazone; Middle Aged; Naproxen; Omeprazole; Potassium Chloride; Prednisone; Pyrroles; Selective Serotonin Reuptake Inhibitors; Spironolactone | 2008 |
Pyrrolo-pyrimidones: a novel class of MK2 inhibitors with potent cellular activity.
Topics: Arthritis, Rheumatoid; Combinatorial Chemistry Techniques; Cytokines; Dose-Response Relationship, Drug; Drug Design; HSP27 Heat-Shock Proteins; Humans; Intracellular Signaling Peptides and Proteins; Leukocytes, Mononuclear; Lipopolysaccharides; Molecular Structure; Monocytes; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Protein Serine-Threonine Kinases; Pyrimidinones; Pyrroles; Tumor Necrosis Factor-alpha | 2008 |
Anti-inflammatory effects of atorvastatin on peripheral blood mononuclear cells and synovial fibroblasts in rheumatoid arthritis.
Topics: Adult; Aged; Antigens, CD; Antigens, Differentiation, T-Lymphocyte; Arthritis, Rheumatoid; Atorvastatin; Biomarkers; Case-Control Studies; CD4-Positive T-Lymphocytes; CD8 Antigens; Cells, Cultured; Enzyme-Linked Immunosorbent Assay; Female; Fibroblasts; Flow Cytometry; Heptanoic Acids; HLA-DR Antigens; Humans; Interleukin-6; Lectins, C-Type; Leukocytes, Mononuclear; Male; Middle Aged; Probability; Pyrroles; Reference Values; Reverse Transcriptase Polymerase Chain Reaction; Synovial Membrane; T-Lymphocyte Subsets; Young Adult | 2009 |
Kinase inhibitors attract attention as oral rheumatoid arthritis drugs.
Topics: Administration, Oral; Aminopyridines; Arthritis, Rheumatoid; Clinical Trials as Topic; Drug Delivery Systems; Drug Design; Humans; Morpholines; Oxazines; Piperidines; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles | 2010 |
Long-term response with everolimus for metastatic renal cell carcinoma refractory to sunitinib.
Topics: Aged; Antineoplastic Agents; Arthritis, Rheumatoid; Carcinoma, Renal Cell; Clinical Trials, Phase III as Topic; Everolimus; Humans; Hypercholesterolemia; Hypertension; Indoles; Kidney Neoplasms; Lung Neoplasms; Male; Pyrroles; Randomized Controlled Trials as Topic; Salvage Therapy; Sirolimus; Sunitinib | 2011 |
Discovery of 4-(5-(cyclopropylcarbamoyl)-2-methylphenylamino)-5-methyl-N-propylpyrrolo[1,2-f][1,2,4]triazine-6-carboxamide (BMS-582949), a clinical p38α MAP kinase inhibitor for the treatment of inflammatory diseases.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Experimental; Arthritis, Rheumatoid; Biological Availability; Caco-2 Cells; Crystallography, X-Ray; Female; Humans; Hydrogen Bonding; In Vitro Techniques; Inflammation; Lipopolysaccharides; Male; Mice; Mice, Inbred BALB C; Microsomes, Liver; Mitogen-Activated Protein Kinase 14; Models, Molecular; Molecular Conformation; Protein Binding; Pyrroles; Rats; Rats, Inbred Lew; Rats, Sprague-Dawley; Stereoisomerism; Structure-Activity Relationship; Triazines; Tumor Necrosis Factor-alpha | 2010 |
Intensive lipid lowering in patients with rheumatoid arthritis and previous myocardial infarction: an explorative analysis from the incremental decrease in endpoints through aggressive lipid lowering (IDEAL) trial.
Topics: Aged; Anticholesteremic Agents; Arthritis, Rheumatoid; Atorvastatin; Cholesterol; Female; Heptanoic Acids; Humans; Male; Middle Aged; Myocardial Infarction; Pyrroles; Randomized Controlled Trials as Topic; Risk Factors; Simvastatin; Statistics as Topic | 2011 |
Estimating transformations for repeated measures modeling of continuous bounded outcome data.
Topics: Arthritis, Rheumatoid; Clinical Trials as Topic; Computer Simulation; Data Interpretation, Statistical; Humans; Janus Kinase 3; Models, Statistical; Piperidines; Pyrimidines; Pyrroles; Quality of Life; Surveys and Questionnaires; Treatment Outcome | 2011 |
CP690,550 inhibits oncostatin M-induced JAK/STAT signaling pathway in rheumatoid synoviocytes.
Topics: Antineoplastic Agents; Arthritis, Rheumatoid; Benzimidazoles; Cells, Cultured; Culture Media, Conditioned; Drug Interactions; Fibroblasts; Humans; Interleukin-6; Janus Kinase 1; Janus Kinase 2; Janus Kinase 3; Oncostatin M; p38 Mitogen-Activated Protein Kinases; Piperidines; Pyridones; Pyrimidines; Pyrroles; RNA, Messenger; Signal Transduction; STAT1 Transcription Factor; STAT3 Transcription Factor; STAT5 Transcription Factor; Synovial Membrane | 2011 |
Pfizer's JAK inhibitor sails through phase 3 in rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Clinical Trials, Phase III as Topic; Drug Delivery Systems; Drug Industry; Humans; Immunosuppression Therapy; Janus Kinases; Piperidines; Pyrimidines; Pyrroles; Receptors, Cytokine; Signal Transduction | 2011 |
A case study of model-based Bayesian dose response estimation.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Bayes Theorem; Chronic Disease; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dose-Response Relationship, Drug; Humans; Longitudinal Studies; Nonlinear Dynamics; Piperidines; Pyrimidines; Pyrroles | 2011 |
Influence of Janus kinase inhibition on interleukin 6-mediated induction of acute-phase serum amyloid A in rheumatoid synovium.
Topics: Acute-Phase Reaction; Arthritis, Rheumatoid; Cells, Cultured; Enzyme Inhibitors; Humans; Interleukin-6; Janus Kinase 2; Janus Kinase 3; Janus Kinases; Piperidines; Pyrimidines; Pyrroles; RNA, Messenger; Serum Amyloid A Protein; Signal Transduction; STAT3 Transcription Factor; Synovial Membrane | 2011 |
Inhibitory effects of the JAK inhibitor CP690,550 on human CD4(+) T lymphocyte cytokine production.
Topics: Antibodies, Monoclonal; Arthritis, Rheumatoid; CD3 Complex; CD4-Positive T-Lymphocytes; Cells, Cultured; Cytokines; Humans; Immunosuppression Therapy; Janus Kinase 3; Lymphocyte Activation; Phosphorylation; Piperidines; Pyrimidines; Pyrroles; Receptors, Antigen, T-Cell; Signal Transduction; STAT Transcription Factors | 2011 |
IL-1β and TNFα-initiated IL-6-STAT3 pathway is critical in mediating inflammatory cytokines and RANKL expression in inflammatory arthritis.
Topics: Animals; Arthritis, Experimental; Arthritis, Rheumatoid; Chronic Disease; Enzyme Inhibitors; Fibroblasts; Gene Expression; Humans; Inflammation; Interleukin-1beta; Interleukin-6; Joints; Mice; Mice, Inbred C57BL; Mice, Inbred DBA; Osteoclasts; Piperidines; Pyrimidines; Pyrroles; RANK Ligand; Signal Transduction; STAT3 Transcription Factor; Tumor Necrosis Factor-alpha | 2011 |
The JAK inhibitor CP-690,550 (tofacitinib) inhibits TNF-induced chemokine expression in fibroblast-like synoviocytes: autocrine role of type I interferon.
Topics: Animals; Antirheumatic Agents; Arthritis, Rheumatoid; Autocrine Communication; Cells, Cultured; Chemokines; Drug Evaluation, Preclinical; Fibroblasts; Humans; Interferon Type I; Interleukin-6; Janus Kinase 3; Mice; Phosphorylation; Piperidines; Pyrimidines; Pyrroles; STAT1 Transcription Factor; STAT3 Transcription Factor; Synovial Membrane; Tumor Necrosis Factor-alpha | 2012 |
Sunitinib-induced hand-foot syndrome in a renal cell carcinoma: a sclerodermatous and rheumatoid arthritis-like case.
Topics: Aged; Antineoplastic Agents; Arthritis, Rheumatoid; Carcinoma, Renal Cell; Female; Hand-Foot Syndrome; Humans; Indoles; Kidney Neoplasms; Pyrroles; Scleroderma, Diffuse; Sunitinib | 2012 |
[Anti-rheumatic effect of JAK-inhibitors].
Topics: Animals; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Humans; Janus Kinases; Mice; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles | 2012 |
Serious adverse events-missing in action: comment on the article by Kremer et al.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Female; Humans; Male; Methotrexate; Pyrimidines; Pyrroles | 2012 |
Kinase inhibition--a new approach to the treatment of rheumatoid arthritis.
Topics: Adalimumab; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Enzyme Inhibitors; Female; Humans; Janus Kinase 3; Male; Piperidines; Pyrimidines; Pyrroles | 2012 |
Atorvastatin inhibits osteoclastogenesis by decreasing the expression of RANKL in the synoviocytes of rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Atorvastatin; Cells, Cultured; Coculture Techniques; Female; Gene Expression Regulation; Heptanoic Acids; Humans; Male; Osteoclasts; Osteogenesis; Pyrroles; RANK Ligand; Synovial Membrane | 2012 |
Tofacitinib for the treatment of moderate to severe rheumatoid arthritis.
Topics: Animals; Antirheumatic Agents; Arthritis, Rheumatoid; Clinical Trials as Topic; Drug Interactions; Humans; Janus Kinase 3; Piperidines; Pyrimidines; Pyrroles; Severity of Illness Index | 2012 |
Regulation of inflammatory responses in tumor necrosis factor-activated and rheumatoid arthritis synovial macrophages by JAK inhibitors.
Topics: Animals; Arthritis, Rheumatoid; Cells, Cultured; Disease Models, Animal; Enzyme Inhibitors; Humans; In Vitro Techniques; Inflammation; Interleukin-6; Janus Kinases; Macrophages; Mice; Mice, Inbred C57BL; NF-kappa B; NFATC Transcription Factors; Nitriles; Piperidines; Proto-Oncogene Proteins c-jun; Pyrazoles; Pyrimidines; Pyrroles; Signal Transduction; STAT1 Transcription Factor; Synovial Membrane; Tumor Necrosis Factor-alpha | 2012 |
FDA approves tofacitinib for rheumatoid arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Approval; Humans; Piperidines; Pyrimidines; Pyrroles; United States; United States Food and Drug Administration | 2012 |
Kinase inhibition in rheumatoid arthritis: a big advance?
Topics: Arthritis, Rheumatoid; Female; Humans; Janus Kinases; Male; Methotrexate; Piperidines; Pyrimidines; Pyrroles; Tumor Necrosis Factor-alpha | 2013 |
Pfizer's first-in-class JAK inhibitor pricey for rheumatoid arthritis market.
Topics: Arthritis, Rheumatoid; Drug Costs; Drug Industry; Humans; Janus Kinases; National Institutes of Health (U.S.); Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; United States | 2013 |
RA gets first oral agent to compete with biologics.
Topics: Administration, Oral; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Biological Products; Clinical Trials, Phase III as Topic; Drug Approval; Female; Humans; Male; Middle Aged; Piperidines; Pyrimidines; Pyrroles; Therapeutic Equivalency; United States; United States Food and Drug Administration | 2013 |
Statins in rheumatoid arthritis--two birds with one stone?
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Atorvastatin; Cardiovascular Diseases; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Risk Factors | 2004 |
Atorvastatin reduces arterial stiffness in patients with rheumatoid arthritis.
Topics: Adult; Aged; Arteries; Arthritis, Rheumatoid; Atorvastatin; Drug Evaluation; Elasticity; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation Mediators; Lipids; Male; Middle Aged; Pulsatile Flow; Pyrroles; Radial Artery | 2004 |
Rheumatoid arthritis treatment progressing.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antirheumatic Agents; Arthritis, Rheumatoid; Atorvastatin; Cyclophosphamide; Drug Therapy, Combination; Heptanoic Acids; Humans; Methotrexate; Pyrroles; Rituximab | 2004 |
Regulation of neurokinin-1 receptor messenger RNA expression in synovial fibroblasts of patients with rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Cells, Cultured; Fibroblast Growth Factors; Fibroblasts; Humans; Interleukin-1; Protein Isoforms; Pyrroles; Receptors, Neurokinin-1; Receptors, Neurokinin-2; RNA, Messenger; Synovial Membrane; Transforming Growth Factor beta; Transforming Growth Factor beta1; Tumor Necrosis Factor-alpha | 2005 |
Statin-induced expression of CD59 on vascular endothelium in hypoxia: a potential mechanism for the anti-inflammatory actions of statins in rheumatoid arthritis.
Topics: Anti-Inflammatory Agents; Arthritis, Rheumatoid; Atorvastatin; CD55 Antigens; CD59 Antigens; Cells, Cultured; Cobalt; Cytoprotection; Deferoxamine; Diterpenes; Endothelial Cells; Endothelium, Vascular; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoxia; Iron Chelating Agents; Mevalonic Acid; Pyrroles; RNA, Messenger; Up-Regulation | 2006 |
Atorvastatine for chronic synovitis due to massive intra-articular cholesterol monohydrate deposition in long-standing rheumatoid arthritis.
Topics: Anticholesteremic Agents; Arthritis, Rheumatoid; Atorvastatin; Cholesterol; Crystallization; Female; Heptanoic Acids; Humans; Middle Aged; Pyrroles; Synovitis | 2006 |
Tolerizing DNA vaccines for autoimmune arthritis.
Topics: Animals; Arthritis, Experimental; Arthritis, Rheumatoid; Atorvastatin; Autoantibodies; Collagen; Cytokines; Heptanoic Acids; Hindlimb; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Interleukin-4; Joints; Male; Mice; Mice, Inbred DBA; Protein Array Analysis; Pyrroles; Systems Biology; Vaccines, DNA | 2006 |
Arthritis clinical trial results revealed.
Topics: Acetates; Antirheumatic Agents; Arthritis, Rheumatoid; Chondroitin Sulfates; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Osteoarthritis; Piperidines; Pyrimidines; Pyrroles | 2007 |
The dual inhibitor of lipoxygenase and cyclooxygenase ML3000 decreases the expression of CXCR3 ligands.
Topics: Acetates; Arthritis, Rheumatoid; Cells, Cultured; Chemokines, CXC; Cyclooxygenase Inhibitors; Down-Regulation; Fibroblasts; Humans; Ligands; Lipoxygenase Inhibitors; Polymerase Chain Reaction; Pyrroles; Receptors, CXCR3; RNA, Messenger; Synovial Membrane | 2008 |
The specificity of JAK3 kinase inhibitors.
Topics: Arthritis, Rheumatoid; Clinical Trials as Topic; Enzyme Inhibitors; Graft Rejection; Humans; Janus Kinase 3; Kinetics; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Quinazolines | 2008 |
Cartilage preservation by inhibition of Janus kinase 3 in two rodent models of rheumatoid arthritis.
Topics: Adjuvants, Immunologic; Animals; Arthritis, Experimental; Arthritis, Rheumatoid; Cartilage, Articular; Collagen; Dose-Response Relationship, Drug; Enzyme Inhibitors; Interleukin-6; Janus Kinase 3; Male; Mice; Mice, Inbred DBA; Piperidines; Pyrimidines; Pyrroles; Rats; Rats, Inbred Lew | 2008 |
Gold nephropathy due to auranofin obscured by tolmetin pseudoproteinuria.
Topics: Anti-Inflammatory Agents; Arthritis, Rheumatoid; Auranofin; Aurothioglucose; Female; Glomerulonephritis; Gold; Humans; Middle Aged; Proteinuria; Pyrroles; Tolmetin | 1984 |
Enhancement of deficient T-cell function in rheumatoid arthritis by tolmetin sodium.
Topics: Arthritis, Rheumatoid; Humans; In Vitro Techniques; Mitogens; Phytohemagglutinins; Pyrroles; T-Lymphocytes; Time Factors; Tolmetin | 1983 |
Long-term therapy with tolmetin in rheumatoid arthritis.
Topics: Adolescent; Adult; Aged; Arthritis, Rheumatoid; Double-Blind Method; Female; Humans; Male; Middle Aged; Pyrroles; Time Factors; Tolmetin | 1983 |
Clinical pharmacology of tolmetin: comparisons in rheumatoid arthritis patients and normal volunteers.
Topics: Adult; Arthritis, Rheumatoid; Biological Availability; Female; Half-Life; Humans; Kinetics; Male; Middle Aged; Prostaglandins E; Pyrroles; Synovial Fluid; Tolmetin | 1983 |
Tolmetin kinetics and synovial fluid prostaglandin E levels in rheumatoid arthritis.
Topics: Adult; Arthritis, Rheumatoid; Female; Half-Life; Humans; Kinetics; Male; Middle Aged; Prostaglandins E; Pyrroles; Synovial Fluid; Tolmetin | 1982 |
Simultaneous determination of tolmetin and its metabolite in biological fluids by high-performance liquid chromatography.
Topics: Arthritis, Rheumatoid; Chromatography, High Pressure Liquid; Humans; Pyrroles; Synovial Fluid; Tolmetin | 1982 |
Nephrotic syndrome induced by tolmetin.
Topics: Arthritis, Rheumatoid; Aspirin; Female; Humans; Middle Aged; Nephritis, Interstitial; Nephrotic Syndrome; Pyrroles; Tolmetin | 1981 |
Inhibition of NFkappaB-mediated interleukin-1beta-stimulated prostaglandin E2 formation by the marine natural product hymenialdisine.
Topics: Adult; Arthritis, Rheumatoid; Azepines; Cells, Cultured; Dinoprostone; Endothelial Growth Factors; Humans; Interleukin-1; Interleukin-8; Lymphokines; NF-kappa B; Phospholipases A; Phospholipases A2; Prostaglandin-Endoperoxide Synthases; Pyrroles; Synovial Membrane; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 1997 |
Dual inhibition of 5-lipoxygenase and cyclooxygenases 1 and 2 by ML3000 reduces joint destruction in adjuvant arthritis.
Topics: Acetates; Animals; Arachidonate 5-Lipoxygenase; Arthritis, Experimental; Arthritis, Rheumatoid; Cyclooxygenase Inhibitors; Disease Models, Animal; Female; Lipoxygenase Inhibitors; Probability; Prostaglandin-Endoperoxide Synthases; Pyrroles; Range of Motion, Articular; Rats; Rats, Inbred Lew; Reference Values; Sensitivity and Specificity; Severity of Illness Index; Statistics, Nonparametric; Treatment Outcome | 2001 |
New antirheumatic agents: Fenoprofen calcium (Nalfon), naproxen (Naprosyn), and tolmetin sodium (Tolectin).
Topics: Anti-Inflammatory Agents; Arthritis, Rheumatoid; Aspirin; Fenoprofen; Gastrointestinal Hemorrhage; Humans; Naphthaleneacetic Acids; Naproxen; Osteoarthritis; Phenylpropionates; Pyrroles; Rheumatic Diseases; Spondylitis, Ankylosing; Tolmetin | 1977 |
Tolmetin sodium.
Topics: Arthritis, Rheumatoid; False Positive Reactions; Female; Gold Sodium Thiomalate; Humans; Middle Aged; Proteinuria; Pyrroles; Tolmetin | 1977 |
Absorption and excretion of tolmetin in arthritic patients.
Topics: Arthritis, Rheumatoid; Biotransformation; Chromatography, Thin Layer; Female; Humans; Intestinal Absorption; Kinetics; Male; Pyrroles; Tolmetin | 1979 |
[Tolmetin (Tolectin) in the long-term therapy of progressive polyarthritis].
Topics: Adult; Aged; Arthritis, Rheumatoid; Female; Humans; Male; Middle Aged; Pyrroles; Tolmetin | 1978 |
Drug fever from tolmetin administration.
Topics: Arthritis, Rheumatoid; Drug Hypersensitivity; Fever; Humans; Male; Middle Aged; Pyrroles; Tolmetin | 1978 |
Nonsteroidal antiinflammatory drugs: new alternatives for rheumatic disease.
Topics: Anti-Inflammatory Agents; Arthritis, Rheumatoid; Drug Therapy, Combination; Fenoprofen; Humans; Ibuprofen; Naproxen; Phenylpropionates; Pyrroles; Tolmetin | 1978 |
Tolmetin and agranulocytosis.
Topics: Agranulocytosis; Arthritis, Rheumatoid; Female; Humans; Middle Aged; Pyrroles; Tolmetin | 1978 |
Anaphylaxis from tolmetin.
Topics: Adult; Anaphylaxis; Arthritis, Rheumatoid; Female; Humans; Pruritus; Pyrroles; Tolmetin | 1978 |
Protein binding of tolmetin.
Topics: Adult; Aged; Arthritis, Rheumatoid; Binding Sites; Binding, Competitive; Erythrocytes; Female; Humans; In Vitro Techniques; Male; Middle Aged; Oleic Acids; Plasma; Protein Binding; Pyrroles; Serum Albumin; Tolmetin; Tryptophan | 1978 |
New nonsteroidal anti-inflammatory drugs.
Topics: Animals; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Aspirin; Fenoprofen; Humans; Ibuprofen; Naphthaleneacetic Acids; Naproxen; Phenylpropionates; Pyrroles; Tolmetin | 1976 |
Pharmacokinetic studies of tolmetin in man.
Topics: Adult; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Benzoates; Dose-Response Relationship, Drug; Female; Half-Life; Humans; Kinetics; Male; Models, Biological; Pyrroles; Toluene | 1975 |
[Testing of the antirheumatic agent tolmetin for its interactions with oral anticoagulants].
Topics: Adult; Aged; Arthritis, Rheumatoid; Blood Coagulation; Drug Interactions; Female; Humans; Male; Middle Aged; Phenprocoumon; Pyrroles; Tolmetin | 1975 |
[Open trial for the evaluation of the therapeutic effectiveness of i-p chlorophenyl-2,5-dimethyl-3-pyrrole acetic acid (clopirac) in rheumatoid arthritis (author's transl)].
Topics: Arthritis, Rheumatoid; Drug Evaluation; Female; Humans; Male; Pyrroles | 1975 |
[Pharmacological study of clopirac, a new anti-inflammatory agent (author's transl)].
Topics: Animals; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Drug Evaluation; Prostaglandins; Pyrroles; Rats | 1975 |
[Review of the clinical studies in rheumatoid arthritis with several non steroid anti-inflammatory agents (author's transl)].
Topics: Anti-Inflammatory Agents; Arthritis, Rheumatoid; Drug Evaluation; Humans; Indomethacin; Ketoprofen; Phenylbutazone; Pyrroles | 1975 |
Tolmetin in breast milk.
Topics: Adult; Arthritis, Rheumatoid; Female; Humans; Milk, Human; Pyrroles; Tolmetin | 1985 |
Clinical evaluation of tolmetin.
Topics: Administration, Oral; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Aspirin; Benzoates; Female; Humans; Male; Middle Aged; Pain; Pyrroles; Radioisotopes; Statistics as Topic; Technetium | 1974 |
Pharmacologic evaluation of tolectin (tolmetin, mcn-2559) and mcn-2891, two anti-inflammatory agents.
Topics: Acetylcholine; Analysis of Variance; Animals; Anti-Inflammatory Agents; Arthritis; Arthritis, Rheumatoid; Behavior, Animal; Benzoates; Blood Pressure; Carrageenan; Dose-Response Relationship, Drug; Edema; Female; Freund's Adjuvant; Heart; Indomethacin; Male; Osteoarthritis; Phenylbutazone; Pyrroles; Quinones; Rats; Saccharomyces cerevisiae; Toluene | 1973 |
Haem biosynthesis studied in patients with rheumatoid arthritis.
Topics: Anemia, Hypochromic; Arthritis, Rheumatoid; Erythrocytes; Heme; Humans; Hydro-Lyases; Levulinic Acids; Porphyrins; Pyrroles | 1972 |
Diaryl pyrroles: a new series of anti-inflammatory agents.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Disease Models, Animal; Edema; Erythema; Female; Guinea Pigs; Hindlimb; Injections, Subcutaneous; Male; Pyrroles; Rats | 1972 |